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 In total, four experiments were conducted to determine the therapeutic and safety effects 
of the nutraceutical, turmeric, and its active ingredient curcumin on canines and equines. Two 
studies were conducted on client-owned, moderately arthritic canines, studying the therapeutic 
and safety effect of curcumin’s anti-inflammatory properties. In Exp. 1, two different dosages, 
500 mg, SID of 95% curcumin and 250 mg, BID of 95% liposomal-curcumin, were evaluated in 
ten moderately arthritic dogs over five months. The dogs in the 95% curcumin group, overall, 
had a greater reduction in pain by Day 60. Exp. 2, was a follow-up experiment to Exp. 1.  In Exp. 
2, two different dosages, 500 mg, SID or 100 mg, SID of 95% curcumin, were evaluated in ten 
moderately arthritic dogs over five months. We observed that dogs in the 500 mg, SID group had 
an overall greater significance in pain reduction by Day 60. Experiment 3 and 4 were conducted 
as a two-part project looking at the antimicrobial and anti-inflammatory properties of turmeric, 
curcumin, and liposomal-curcumin. The purpose of these studies were to investigate both form 
and dose of turmeric and its active ingredient, curcumin, on reducing opportunistic bacteria 
found in the equine hindgut. The bacterial strains of interest included Streptococcus 
bovis/equinus complex (SBEC), Escherichia coli K-12, Escherichia coli general, Clostridium 
difficile, and Clostridium perfringens. Exp. 3, was a two-part in vitro study; the first part looked 
at the antimicrobial effects of turmeric, curcumin, and liposomal-curcumin (LIPC) on reducing 
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opportunistic bacteria found in the equine hindgut, including SBEC (P = 0.006), E. coli K-12 (P 
= 0.50), E. coli general (P = 0.11), C. difficile (P < 0.0001), and C. perfringens (P = 0.24). The 
follow-up in vitro 24 h batch culture examined four different dosages (15 g, 20 g, 25 g, and 30 g) 
of 500 mg/g of LIPC, at reducing the concentration of opportunistic bacteria. These results were 
utilized to determine the dosing rate in vivo. Exp. 3, in vitro, evaluated the efficacy of 
antimicrobial and anti-inflammatory properties of LIPC dosed at 15, 20, 25, and 35 g. These 
results were utilized to determine the dosing rate in vivo. Exp. 4, in vivo, evaluated the efficacy 
of antimicrobial and anti-inflammatory properties of LIPC dosed at 15, 25, and 35 g compared to 
a control. In vivo, LIPC’s antimicrobial properties, at 15 g, significantly decreased (P = 0.02) 
SBEC compared to other treatments. In addition, C. perfringens tended (P = 0.12) to decrease as 
LIPC dose increased. Non-significant results in digestion, blood parameters, and range of motion 
suggest there were no adverse side effects from oral dosing increasing doses of curcumin. 
Valerate decreased (P = 0.005) linearly as LIPC dose increased. As LIPC dose increased, 
butyrate and iso-valerate decreased (P ≤ 0.03) linearly. However, acetate tended (P = 0.10) to 
increase linearly as the dose of LIPC increased. Treatment did not affect (P ≥ 0.19) any of the 
other individual VFAs measured, but increasing doses of LIPC tended (P = 0.10) to increase 
total VFA concentrations. Additionally, LIPC tended (P = 0.11) to increase total VFA 
concentrations when compared to control. In the future, further work should be conducted 
examining liposomal-curcumin’s antimicrobial properties in canine and anti-inflammatory 
properties in equine over a longer period of time 
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CHAPTER 1 
LITERATURE REVIEW 
INTRODUCTION 
 Currently, the topic of alternative care, specifically dietary supplements and 
nutraceuticals, is extremely controversial. Dietary supplements are defined as an herb or other 
phytochemical, amino acid, vitamins, and minerals added into the diet (Mechanick, 2003). 
Nutraceuticals are defined as dietary supplements that contain a concentrated form of a bioactive 
substance, which is derived from food (Mechanick, 2003). In 1994, the United States Congress 
passed the Dietary Supplement Health and Education Act (DSHEA). The DSHEA promotes the 
use of dietary supplements and nutraceuticals based on their presumed safety and medicinal 
properties. However, there are no federal regulations and little scientific evidence on the health 
benefits and potential side effects of nutraceuticals. Due to an increasing push for new, safer 
alternative care, nutraceuticals are becoming a more popular choice, resulting in a need for safety 
and efficiency research to be conducted.  
NUTRACEUTICALS 
 Pharmaceuticals have a high risk of toxicity and adverse side effects; because of this, 
there is push for alternative treatments in the form of food supplements. A nutraceutical, 
typically plant based, food source, which provides medical or health benefits including the 
prevention and treatment of a disease (Rajat et al., 2012). Stephen DeFelice, MD, the founder 
and chairman of the Foundation for Innovation in Medicine, coined the word “nutraceutical” in 
1989, from the words “nutrition” and “pharmaceutical” (Rajat et al., 2012). However, the use of 
  
2 
food supplements to treat diseases dates back to Hippocrates, the father of medicine, (460-377 
BC) when he predicted the health benefits of foods (Singh et al., 2011). Nutraceuticals are 
gaining popularity with health professionals and the public, since certain foods play an important 
role in maintaining normal functions in the human body without the risk of adverse side effects. 
Currently, there are over 470 nutraceuticals with documented health benefits (Singh et al., 2011; 
Rajat et al., 2012). Nutraceuticals are classified into two types, traditional foods and non-
traditional foods. Traditional food is defined as natural, whole food with new information about 
potential health qualities. For example, omega-3 fatty acids, in salmon and other seafood, help 
reduce undesirable cholesterols. Non-traditional foods result from agriculture, crop and animal 
breeding or adding nutrients and ingredients to boost traditional food’s nutritional value. 
Examples include orange juice that is fortified with calcium; milk fortified with vitamins; and 
crops fortified with vitamins, minerals, and omega-3 fatty acids. However, to date few focus 
directly on osteoarthritis.  
Unlike pharmaceuticals, there are no FDA regulations for the health claims of 
nutraceuticals or non-traditional foods (Rajat et al., 2012). Even though there are few regulations 
on the health claims of nutraceuticals, safety must be assured in advance. Therefore, extensive, 
independent, testing must be conducted on a nutraceutical before health professionals 
recommend it to their patients. During the research process, nutraceuticals can be classified as 
potential or established nutraceuticals. Potential nutraceuticals provide a promising approach 
toward a particular health or medical benefit, while established nutraceuticals have multiple, 
independent, peer-reviewed, research reports backing up their claimed benefits (Sanghi et al., 
2008; Singh et al., 2011).  
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 Herbal medicine is increasing its popularity in veterinary medicine. Popularity may be 
due to low cost and a belief that there are minimal to no side effects. Herbal medicine is 
becoming a common treatment for mastitis occurrences, foot-and-mouth disease outbreaks, skin 
allergies, food poisonings, tympany, and expulsion of placentae. In the past, nutraceuticals were 
a common therapy for livestock in treating a variety of diseases including, hepatitis, chronic 
heart disease, skin disorders, wounds, and arthritis (Sanghi et al., 2008; Mahima et al., 2013). 
Some nutraceuticals affect the progression of arthritis by preventing degradation and enhancing 
the repair of joint cartilage (Sanghi et al., 2008). 
TURMERIC 
 Turmeric is a rhizomatous herbaceous perennial plant, Curcuma longa Linn, belonging to 
the ginger family, Zingiberaceae (Chan et al., 2009). Turmeric is native to Southeast India and 
grows in temperatures between 20-30° C, with high amounts of rainfall. Once picked, typically 
in August, the rhizomes are boiled, dehydrated, and then ground into orange-yellow powder, 
which is used for curries, dyeing, and mustard condiments (Prasad et al., 2011). Turmeric, also 
known as haldi, is one of the oldest sources of spice, coloring pigments, and medicine, dating 
back to 1900 B.C. (Hassaninasab et al., 2010). In culinary, turmeric is used in many South and 
Southeast Asian dishes, typically in the powder form. Turmeric has also been a major part of 
Siddha medicine for over a thousand years as a remedy for stomach and liver ailments, healing 
sores, and has antimicrobial properties. Turmeric is said to help with a range of diseases and 
conditions including, skin, pulmonary, gastrointestinal, aches, pains, wounds, sprains, liver 
disorders, and cancer (Prasad et al., 2011). Turmeric’s anti-inflammatory properties are said to 
come from an antioxidant, curcumin, specifically diferuloylmethane. In in vitro studies, 
curcumin was able to inhibit the production of cyclooxygenase-II enzymes, lipoxygenases, 
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prostaglandins, and nuclear factor-kappaß (NF-Kß), which are involved in the cascade of 
inflammation (Rosenbaum et al., 2010). According to the National Center for Complementary 
and Alternative Medicine, turmeric has little reliable evidence to support these claims due to the 
few studies that have been conducted (Esatbeyogula et al., 2012). Even though there have been 
over 3,000 curcumin related studies to date, most are in vitro and due to the poor bioavailability 
it is hard to extrapolate the results in an animal model (Belcaro et al., 2010).  
Chemical Composition of Turmeric 
 Turmeric is comprised of protein (6.3%), fat (5.1%), minerals (3.5%), carbohydrates 
(69.4%), and moisture (13.1%) (Chattopadhyay et al., 2004). Essential oils can be collected from 
turmeric by steam distillation of the rhizomes in the amounts of: alpha-phellandrene (1%), 
sabinene (0.6%), cineol (1%), borneol (0.5%), zingiberene (25%), and sesquiterpines (53%) 
(Chattopadhyay et al., 2004). Curcumin, the active ingredient of turmeric (3-4%), was first 
isolated in 1815, by Roughley and again by Whiting in 1973. It was noted that turmeric’s melting 
point is at 176° C and forms a reddish-brown salt with alkali, which is soluble in ethanol, alkali, 
ketone, acetic acid, and chloroform (Chattopadhyay et al., 2004).  
Curcuminoids 
The most important chemical component of turmeric is the group of active ingredients, 
curcuminoids. Curcuminoids consist of diferyloymethane (curcumin I), demthoxycurcumin 
(curcumin II), and bis-demthoxycurcumin (curcumin III), which are mostly seen in commercial 
supplements, structures listed below. In addition to this vital, active ingredient, turmeric also 
contains volatile oils, including tuermerone, atlantone, and zingiberene. Curcuminoids are 
natural phenols and give turmeric its yellow coloring. This group makes up roughly 2-6% of the 
spice, with curcumin, belonging to the diarylheptanoid group, as the main compound (Jagetia 
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and Aggarwal, 2007; Wynn and Fougere, 2008). Typical commercial products contain 77% 
curcumin, 17% demethoxycurcumin, and 3% bis-demethoxycurcumin. These curcuminoids are 
said to work synergistically and have a greater effect than if used alone (Wynn & Fougere, 
2008). Commercial curcumin is often 95% curcumin, instead of 100%, because there is not an 
increase of bioavailability from 95% to 100%. However, the cost to manufacture 95% curcumin 
is less than 100% curcumin (Jagetia and Aggarwal, 2007; Wynn and Fougere, 2008).  
Curcumin is known for its wide range of medicinal benefits, including anti-inflammatory, 
antioxidant, antimicrobial, wound healing, and anti-tumor properties (Zhu et al., 2014). In in vivo 
studies, it has been suggested that, despite the poor bioavailability, curcumin can cross the blood 
brain barrier, making it a potential treatment for neuro-inflammatory and neurodegenerative 
conditions in the central nervous system (Zhu et al., 2014). These properties are due to 
curcumin’s chemical features and its ability to interact with signaling molecules (Zhu et al., 
2014). In Ayurvedic medicine, turmeric is used as an anti-inflammatory and in Chinese 
medicine; it is used for stimulant, aspirant, carminative, astringent, detergent, and as a diuretic 
(Li et al., 2011). Curcumin has been used for thousands of years in Eastern medicine; however, 
the biological actions have been recently studied (Li et al., 2011). Throughout multiple studies 
on a variety of species, curcumin has potential for being a therapeutic agent for inflammatory 
diseases, including inflammatory bowel disease, pancreatitis, and arthritis. In clinical trials, it has 
been reported that curcumin may have an anti-cancer effect, as a chemoprevention agent (Li et 
al., 2011). Overall, curcumin and turmeric are considered relatively safe under daily 
consumption. However, in a human study, high dosages of curcumin over a period of time 
caused mild side effects, including nausea and diarrhea. In more recent studies, curcumin was 
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found to affect iron metabolism by chelating iron and suppressing the protein hepcidin, resulting 
in iron deficiency.  
Numerous studies have been conducted on the medicinal properties of turmeric and its 
active ingredient, curcumin. However, little has been studied in regards to metabolic pathways. 
In 2010, Hassaninasab et al. identified a curcumin-converting enzyme in the cecum, CurA, a sub-
strain of Escherichia coli. The bioavailability of curcumin is noted to be minimal due to it being 
hydrophobic, with low intrinsic activity, poor absorption, and a high rate of metabolism and 
elimination from the body (Anard et al., 2009). However, curcumin can be encapsulated into 
liposomes, liposomal-curcumin, to increase bioavailability (Li et al., 2007; Li et al., 2011). 
Liposomes can carry both hydrophobic and hydrophilic molecules, which makes them ideal for 
drug delivery (Anard et al., 2009). Turmeric and curcumin have been suggested to have 
numerous medicinal benefits and seem to have a relatively low risk of adverse side effects; 
however, it is vital to conduct research to identify to what degree of anti-inflammatory and 
antimicrobial properties they have, how safe they are to use, and the proper dosage for mammals, 
specifically canine and equine. 
OSTEOARTHRITIS  
 Osteoarthritis is a disease that has been described for over a hundred years (Nelson et al., 
2011). Currently there are about 27 million Americans diagnosed, but numbers are expected to 
reach 67 million by 2030 (Lawley et al., 2013). Osteoarthritis is the most common form of 
arthritis in humans, dogs, and horses. In almost every form of arthritis there is a loss of bone or 
cartilage that results in changes in the shape of joints (Lawley et al., 2013). Osteoarthritis, also 
known as degenerative joint disease (DJD), is a chronic inflammatory joint disease, which causes 
pain, soreness, stiffness, swelling, and lameness; due to the diminished cushion and changes in 
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the synovial fluid (Vaughn-Scott et al., 1997; Pasquini et al., 2007). Osteoarthritis affects the 
entire synovial joint, including cartilage, synovial fluid, and bone. This disease is characterized 
by degeneration of the cartilage and soft tissues, hypertrophy of bone at the margins, and 
changes in the synovial membrane (Vaughn-Scott et al., 1997; Pasquini et al., 2007). Mechanical 
stress is thought to induce changes in biochemical factors within affected joints, leading to 
articular cartilage degradation (Renberg, 2005). The disease process limits the amount of protein, 
released from the cartilage’s cells, to repair cartilage in the joints; this is referred to as pitting and 
fraying of cartilage (Gupta et al., 2009; Gupta et al., 2011; Fleck et al., 2013; Lawley et al., 
2013). Pitting and fraying results in the cartilage losing its elasticity and protective surface due to 
enzymatic cleavage of proteoglycans (Reid and Miller, 2008). As the cartilage continues to break 
down and deteriorate completely, it causes friction between the bones, which leads to 
inflammation, thickening of soft tissues, and loss of mobility of the joint (Reid and Miller, 2008). 
Trying to maintain its normal balance of injury and repair, as the cartilage wears away, the joint 
begin to lose its normal shape and the space between the joint narrow. Osteophytes (spurs) 
formation begins where the ligaments and joint capsule attach to the bone. In addition, fluid 
filled cysts form, and fragments of bone and cartilage can be found floating in the joint space 
(Gupta et al., 2009; Gupta et al., 2011; Fleck et al., 2013; Lawley et al., 2013). All of the changes 
to the joints and bones can cause pain, swelling, and the joint may even appear enlarged. 
JOINT ANATOMY 
Osteoarthritis has multiple causes and risk factors, however once the cartilage is lost, the 
joint fails (Erye et al., 2006). There are three different types of joints, fibrous, cartilaginous, and 
synovial. Fibrous and cartilaginous joints consist of fibrous tissue or hyaline cartilage, which 
allow little or no movement. Synovial joints are made up of synovial fluid and dense irregular 
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connective tissue, which creates a synovial joint capsule allowing the joints to freely move 
(Pasquini et al., 2007). The main focus will be on the synovial joint, especially the ball and 
socket (hip and shoulder) and hinge joints (elbow), because these types of joints are most 
commonly affected by osteoarthritis (Pasquini et al., 2007). The synovial fluid in the synovial 
joint capsule provides nutrients, lubrication, and a cushion for articular cartilage (Vaughn-Scott 
et al., 1997; Pasquini et al., 2007). Articular cartilage, which is composed of hyaline cartilage, is 
avascular tissue consisting of chondrocytes embedded within an extracellular matrix of 
collagens, proteoglycans, and non-collagenous proteins. Articular cartilage reduces friction and 
makes movement of the synovial joints less painful (Bos et al., 2010). The cartilage is 75% water 
and divided into four zones; superficial, middle, deep, and calcified zones (Tomiosso et al., 
2005). Articular cartilage consists of three zones (I through III), which are delineated from the 
calcified cartilage (Zone IV) (Renberg, 2005). The tissue’s material strength depends on the 
cross-linking of collagen and the zoning changes within tissue depth. Hyaline cartilage (50% 
cartilage, 35% proteoglycan, 10% other glycoproteins, and 5% other lipids and minerals) covers 
the subchondral bone and forms the articulating surface in the joint (Pasquini et al., 2007; Bos et 
al., 2010). The hyaline cartilage, which has a high content of collagen type II, serves as a shock 
absorber by distributing pressure from the load over the subchondral bone. In healthy joints, 
there is a fine balance between injury and repair amongst chondroblasts and chondroclasts 
(Gupta et al., 2009; Gupta et al., 2011; Fleck et al., 2013; Lawley et al., 2013). However, in 
osteoarthritis this balance is disrupted by an overproduction of osteoblasts that can cause pain 
and swelling. Early diagnosis of osteoarthritis is key to help prevent further damage and try to 
repair the damage already done. 
Measuring Joint Mobility 
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 Osteoarthritis patients struggle with limited range of motion (ROM), a reduction in the 
ability to move one’s joints. Pain, stiffness, and swelling, all symptoms of osteoarthritis, can 
hinder mobility. Measuring the ROM can help identify what condition the articular surface, joint 
capsule, ligaments, and muscles, are in (Lin et al., 2013). Assessing the ROM is widely used in 
human medicine and is becoming more popular in canine and equine veterinary medicine, as 
more patients are being diagnosed with arthritis. Universal goniometry is a commonly preferred 
way to measure ROM in humans and other species (Ates et al., 2011). A goniometer is an 
affordable, reliable, commonly used, non-invasive tool used to measure flexion and extension 
degrees of joint mobility in the forelimbs and hind limbs in animals, as well as humans during 
physical therapy sessions. When using a goniometer, place the tool over the fulcrum of the joint, 
aligning the stationary arm with the stationary line of the body. Move the desired joint, either 
flexed or extend, and follow the moving line of the body with the moving arm of the goniometer; 
look at the readings on the goniometer for the degree of range of motion. 
Erythrocyte Sedimentation Rate 
The erythrocyte sedimentation rate (ESR) test, also known as the sed rate, sedimentation 
rate, and Autozero Westergren sedimentation rate, is a quick and simple test that has been used 
for many years to detect inflammation associated with infections, autoimmune diseases, and 
arthritis. A Polish pathologist, Edmund Biernacki, invented the ESR test in 1897. In 1918, two 
Swedish pathologists, Robert Sanno Fahraeus and Alf Vilhelm Albertsson Westergren used 
sodium citrate-anticoagulant specimens. This method of the test is widely used today and known 
as the Westergren method (Provet, 2014). 
 Due to the ESR test not being specific, it is used in addition to other blood tests, 
including C-reactive protein, antinuclear antibody (ANA), and rheumatoid factor. Typically, 
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ESR tests are ordered when a condition or disease is suspected to cause some form of chronic 
inflammation in the body. For example, people who suffer from arthritis may have an ESR test 
run to detect the amount of inflammation in the joints. ESR measures the rate at which red blood 
cells settle out over one hour. The test is performed with anti-coagulated blood, typically in an 
ethylenediaminetetraacetic acid (EDTA) tube that is mixed with a tube containing sodium citrate 
and then is placed in an upright 150 mm tube, also known as a Westergren tube. After an hour, 
the rate at which the red blood cells have fallen is reported in millimeters of plasma per hour 
(Blair Street Vet Hospital, 2014). The ESR test works by a precise balance of pro-sedimentation 
factors, specifically fibrinogen, and resisting sedimentation factors, such as the negative charge 
of erythrocytes. During a state of inflammation, the fibrinogen increases, causing the red blood 
cells to stick together in a stacked pattern known as rouleaux. The stacked erythrocytes are 
denser and cause the cells to settle faster than normal (Provet, 2014).  
STAGES OF OSTEOARTHRITIS 
Osteoarthritis is a progressive disease that consists of four stages. In stage one of 
osteoarthritis, minor bone spurs begin to develop. The cartilage matrix begins to break down due 
to chondrocyte’s metabolism being affected and increasing the production of matrix destroying 
enzymes, matrix metalloproteinases (MMP). The severity of cartilage lesions can be correlated 
with the levels of collagenase present (MMP-1) (Reid and Miller, 2008). Cartilage lesions 
disrupt the function of cartilage, increasing friction and inflammation in the joints, resulting in 
pain. Stage two of osteoarthritis is considered the “mild” stage. This stage involves erosion of the 
bone due to the cartilage lesions. This can cause new bone growth, osteophytes, also called bone 
spurs, which affect normal joint movement. In this stage, proteoglycan and collagen fragments 
are released into the synovial fluid (Lawley et al., 2013). In the adult dog, proteoglycan turnover 
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is quicker (300 days) than estimated collagen turnover (120 years). Marked proteoglycan loss of 
articular cartilage is irreversible and results in joint degeneration (Renberg, 2005). Stage three is 
considered “moderate” osteoarthritis. The cartilage, in-between the bones, thins out and loses 
cushion. The space between the bones is also narrowing, causing grinding between the adjacent 
subchondral bones (Renberg, 2005). During stage three, symptoms are more severe and 
inflammation begins to occur. Production of synovial macrophage occurs, including MMP, 
cytokines (interleukin-1), and tumor necrosis factor-alpha (Renberg, 2005). Once the synovial 
macrophages are produced they can destroy tissues by diffusing back into the cartilage and can 
also stimulate chondrocytes. The fourth and final stage of osteoarthritis is considered “severe” 
osteoarthritis. In this stage the joint space is dramatically reduced, the cartilage is almost gone, 
and joint mobility is reduced greatly (Renberg, 2005). 
TYPES OF OSTEOARTHRITIS 
There are two types of osteoarthritis, primary and secondary. Primary osteoarthritis, also 
known as “wear and tear” is characterized by aging or normal wearing of the cartilage in the 
joint. This form of osteoarthritis is more commonly diagnosed. Secondary osteoarthritis is 
characterized by a specific cause, such as an injury, secondary issue from obesity, genetics, 
inactivity, or other diseases. An injury to a bone can cause an earlier onset of osteoarthritis. 
Obesity, and inactivity, which leads to obesity, can cause the joint to wear away faster due to 
extra pressure that is exerted on a joint (Vaughn-Scott et al., 1997). According to the Arthritis 
Foundation, for every pound gained, three pounds of pressure are added to the knees and six 
pounds of pressure are added to the hips (Vaughn-Scott et al., 1997). Despite the type of 
osteoarthritis, the treatment for both primary and secondary are the same (Vaughn-Scott et al., 
1997). 
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TREATMENTS OF OSTEOARTHRITIS 
When treating osteoarthritis, the main goals are to reduce pain and inflammation, 
improve joint function, eliminate or control the cause of arthritis, and even halt the process via 
surgery. Treatment can either occur through therapy or medication. Osteoarthritis is more 
common in overweight dogs; therefore, putting the dog on a strict diet to promote weight loss 
may result in a decrease in mechanical stress on the joints. By incorporating a weight loss 
program into the treatment plan, this can lower the amount of medication required. Along with 
strict dieting, a modified exercise plan should also be established for the dog. An exercise 
program can help in reducing weight while maintaining range of motion and muscle mass. 
Modified, low-impact exercises, such as walking or swimming, can also strengthen joint 
supporting structures, muscles, ligaments, tendons, and joint capsules (Vaughn-Scott et al., 
1997). These forms of treatment can also be applied to other animal species and humans. 
Non-Steroidal Anti-Inflammatory Agents (NSAIDs) 
Pharmacological management of osteoarthritis includes steroidal or non-steroidal anti-
inflammatory drugs (NSAIDs). These drugs do not address the underlying issue; they just control 
pain and inflammation. NSAIDs work against prostaglandins, a family of chemicals that are 
produced by cells and promote inflammation. During inflammation, proliferation of 
prostaglandins can result in pain, fever, and increased platelet clumping (Vaughn-Scott, et al., 
1997). The cells that produce prostaglandins are called cyclooxygenase (COX). There are two 
forms of COX enzymes; COX-I enzymes produce prostaglandins that support platelet clumping 
and protect the stomach lining, and COX-II enzymes produce prostaglandins that are responsible 
for pain and inflammation. Since NSAIDs inhibit both forms of COX enzymes, NSAID usage 
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can result in gastrointestinal side effects, including ulceration, vomiting, anorexia, melena, and 
abdominal pain (Vaughn-Scott, et al., 1997).  
Aspirin (acetylsalicylic acid) was the first NSAID to be used in modern medicine and still 
is widely used. Aspirin, despite its side effects, is commonly recommended in veterinary 
medicine for dogs that suffer from osteoarthritis, due to it being relatively inexpensive. However, 
studies have shown that aspirin can decrease chondrocyte production of collagen and 
proteoglycans and can enhance cartilage degradation over time (Vaughn-Scott, et al., 1997). 
Aspirin is also a unique NSAID, in the fact that it prolongs blood clotting for 4-7 days post-
consumption. This makes in an ideal drug for preventing blood clots that can cause heart attacks 
and strokes (Vaughn-Scott, et al., 1997). However, excessive use can cause internal bleeding and 
decrease surgical recovery prognosis. Since there are many problems associated specifically with 
taking aspirin for osteoarthritis treatment, other NSAIDs are becoming more popular. The six 
most commonly used NSAIDs, prescribed by veterinarians, other than aspirin, for osteoarthritis 
patients, include RimadylTM, DeramaxxTM, EtogesicTM, MetacamTM, ZubrinTM, and PrevicoxTM 
(Vaughn-Scott, et al., 1997). 
Corticosteroids 
            Corticosteroids and glucocorticosteroids, often referred to as steroids, can be considered 
lifesaving and increase the quality of life (McDonald and Langston, 1995). Cortisone is a 
hormone that naturally occurs in the cortex of the adrenal gland. This is where the “cortico” 
prefix comes from. Corticosteroids are produced from the same chemical base that produces sex 
hormones (Jones and Dohetry, 1996). Cortisol is naturally produced when an animal gets 
stressed; however, man-made cortisol is 5-6 times stronger than naturally produced cortisol. Any 
production, natural or drug induced, of cortisol has a negative feedback and slows or stops 
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natural production. Suppression of naturally produced cortisol typically occurs within 12-48 h 
and takes a few days to start the process back up (Jones and Dohetry, 1996). Stopping the use of 
steroids quickly can result in a withdrawal syndrome, which includes fatigue, joint pain, 
stiffness, tenderness, and fever (, 2009).  
            Corticosteroids are the most used and misused, pharmaceutical in veterinary medicine 
(McDonald and Langston, 1995). Steroids, generally in an oral tablet, are used for stress 
response, immune system issues, inflammation, nutrient metabolism, and maintaining electrolyte 
levels in the blood (McDonald and Langston, 1995). Corticosteroids are a popular treatment plan 
for patients suffering from arthritis because they are extremely effective in relieving pain and 
inflammation (Fields, 2009). Steroids inhibit the production of arachidonic acid, which can stop 
the inflammation and stop the production of prostaglandins, similar to NSAIDs (Jones and 
Dohetry, 1996). However, when using steroids the body cannot separate the anti-inflammatory 
properties from the immunosuppressant properties (Jones and Dohetry, 1996). Therefore, low 
doses of steroids are used to suppress inflammation and high doses of steroids are used as 
immune-suppressants (McDonald and Langston, 1995). Since steroids affect nearly all cells of 
the body, their benefits are widespread; however, their side effects can be long lasting and 
devastating (Jones and Dohetry, 1996). The side effects, which vary depending on the dose and 
duration of steroid use, include sore mouth, weight gain, osteoporosis, high blood sugar levels 
(diabetes), cataracts, insomnia, gastrointestinal bleeding and ulcers, suppressed immune system, 
fluid retention, atherosclerosis resulting in increased risk of heart disease, and aseptic necrosis. 
To reduce the probability of side effects from steroid use, one must avoid using steroids on a 
daily basis and no longer than 3-4 months without re-evaluating organ functions. Due to the 
devastating side effects of steroid use, alternative medicine such as acupuncture, nutraceuticals, 
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and physical therapy are becoming more popular as treatments for osteoarthritis, especially in 
veterinary medicine.  
 Glucosamine 
As the body ages, the production of glucosamine slows down; therefore, it is important to 
supplement glucosamine to avoid joint issues (Narvy et al., 2010). Glucosamine (2-amino-2-
deoxy-D glucose), the most abundant monosaccharide, is a naturally occurring compound 
composed of sugar and amino acids. Glucosamine has been used for nearly 40 years in human 
medicine (Narvy et al., 2010). Glucosamine supplements are extracted from crustacean 
exoskeletons or from fermentation of grains such as corn or wheat (Narvy et al., 2010). It is 
strictly used as a dietary supplement in the United States, but is a regulated pharmaceutical 
throughout Europe (Simoens and Laekeman, 2010). There are three different types of 
glucosamine; glucosamine sulfate, glucosamine hydrochloride, and N-acetyl-glucosamine. 
However, glucosamine sulfate may be more effective for arthritis treatment because sulfate is 
needed to produce cartilage and the other two forms of glucosamine do not contain sulfates 
(Narvy et al., 2010). Glucosamine supplements are often combined with chondroitin sulfate. 
Chondroitin sulfate addresses the disease process of arthritis by aiding in the repair of damaged 
connective tissue. It is also beneficial to stress injuries, by keeping joints hydrated and helps 
protect existing cartilage breakdown (Irsay et al., 2010). 
Glucosamine is one of the most commonly used nutraceuticals, especially for arthritic 
patients, due to it being involved in the body’s production of joint lubrication, shock absorption, 
and maintaining healthy cartilage and joint function (Narvy et al., 2010). Glucosamine is the 
precursor in the biochemical synthesis of glycosylated proteins and lipids, glycosaminoglycans. 
Glycosaminoglycans are a major component of joint cartilage and the extracellular matrix of 
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articular cartilage (Narvy et al., 2010). Glucosamine also aids in the rebuilding of damaged 
cartilage and is a building block for articular cartilage (Narvy et al., 2010). Glucosamine has 
anti-inflammatory properties by inhibiting synthesis of degradation enzymes, increasing 
synthesis of extracellular matrix, and reduces apoptosis of articular chondrocytes (Narvy et al., 
2010). Glucosamine is also good for nail growth, tendons, skin, eyes, synovial fluid, ligaments, 
heart valves, and mucous secretions of the digestive, respiratory, and urinary tract (Irsay et al., 
2010). Glucosamine supplements have little to no side effects when used at the recommended 
dose; however, if taken above the recommended dose, it can cause damage to pancreatic cells 
and increase the risk of diabetes. Short-term side effects of glucosamine include stomach upset, 
constipation, diarrhea, headaches, and rashes (Simoens and Laekeman, 2010). In recent years, in 
a series of preliminary experiments, researchers have evaluated several nutraceuticals, 
individually and in combination, with several other supplements, and found that they are 
significantly effective in ameliorating arthritic pain (Gupta et al., 2009; Gupta et al., 2011). 
OSTEOARTHRITIS IN DOGS 
Osteoarthritis is the most common type of arthritis in dogs and is the most common 
source of chronic pain in older dogs (Vaughn-Scott, et al., 1997). This is due to the constant 
wearing away of the cartilage from dogs running, jumping, and other strenuous exercise. 
Arthritis commonly affects large breed dogs, i.e. German Shepherds, Labradors Retrievers, 
Siberian Huskies, and Rottweilers, more than small breed dogs. Prevalence of osteoarthritis can 
be as high as 20% in dogs more than a year old, with middle-aged and older dogs being at higher 
risk. Dogs that are diagnosed with arthritis tend to be lethargic, have difficulty moving from a 
sitting or lying position, cracking joints, stiffness, muscle wastage, and visible pain (Gupta et al., 
2009; Gupta et al., 2011). Diagnosing osteoarthritis in dogs begins with owners observing the 
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pain and stiffness while the animal is running, walking, jumping, or rising from a lying or sitting 
position. Radiographic evidence, patient symptoms, and osteoarthritis risk factors, such as age, 
gender, and body mass index, can all aid in predicting the risk of rapid, highly predictable joint 
degradation (Gupta et al., 2011). During physical examinations, the patient may show signs of 
pain, including whining, biting, or trying to move away. Radiographs can show the breaking 
down of cartilage between bones and narrowing joint space. Domestic species including cats and 
dogs can be diagnosed for arthritis via ultrasounds. In addition, a multitude of blood tests can be 
used to determine the degree of inflammation in the joints from arthritis, aiding in the diagnosis. 
One test used to assess inflammation is the erythrocyte sedimentation rate test along with 
complete blood counts and chemistry panels. By properly diagnosing patients with osteoarthritis, 
this will help establish a future plan to help ease pain, prevent further damage, and overall 
increase the quality of life.  
Along with osteoarthritis, dogs may also suffer from hip dysplasia, a form of 
osteoarthritis present in the ball and socket joints. Hip dysplasia is an inherited condition from 
improperly formed hip joints typically seen in large breed dogs (WebMD, 2013). Dogs that 
suffer from inherited hip dysplasia, show signs within the first year and should be spayed or 
neutered to avoid passing this genetic tendency of malformation to offspring. Bulldogs, St. 
Bernard’s, Blood Hounds, and Boykin Spaniels are a few examples of breeds that are at a higher 
risk factor for developing hip dysplasia. Dogs can also be at risk for hip dysplasia if there is 
excessive weight gain during the early stages of growth, typically 3-8 months of age, and from 
putting excessive pressure on the hip joint from strenuous exercise. Hip dysplasia is caused from 
an abnormal development of the hip joint, leading to excess laxity in the hip joint. Laxity in the 
hip joint can cause stretching of the supporting ligaments, joint capsules, and surrounding 
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muscles, leading to permanent damage to the anatomy of the hip joint. The permanent damage to 
the anatomy causes the poorly developed head of the femur to loosely fit into a shallow 
acetabulum (WebMD, 2013). OFA, Orthopedic Foundation for Animals, radiographs can also be 
performed to diagnose hip dysplasia. According to the Orthopedic Foundation for Animals, OFA 
radiographs must be performed with the animal in dorsal recumbancy with rear limbs extended 
parallel. The stifles are rotated inward and the pelvis is symmetric. This type of radiograph 
allows veterinarians to assess how the femoral head fits into the acetabulum, which is the 
diagnosis of hip dysplasia (WebMD, 2013). 
OSTEOARTHRITIS IN HORSES 
Musculoskeletal diseases, including osteoarthritis, affect horses the same way it affects 
humans and dogs. Osteoarthritis is a degenerative, career-compromising disease in horses and is 
responsible for 60% of lameness in performance and pleasure horses (Frisbie et al., 2002). 
Osteoarthritis can be emotionally and financially draining for the horse’s owner. Therefore, 
finding a safe, effective, and economically sound treatment is vital for horse owners and their 
horses. 
Horses can get osteoarthritis by two means, normal forces on damaged cartilage or 
damaging force on normal cartilage (Farinacci et al., 2009). Horses need to keep up with 
physical demand, which can lead to abnormal forces, including heavy athletic activity resulting 
in loss of joint or limb stability. The most common joints susceptible for osteoarthritis are the 
knee, fetlock, coffin, pastern, and hock (Todhunter and Lust, 1990). If a horse has osteoarthritis, 
their symptoms are commonly very subtle and non-specific. These symptoms, include spending 
more time laying down, difficulties getting up, lethargy, behavior changes, slow or stiffness, 
abnormal gait, swollen joints, decreased appetite, and unexplained muscle wastage (Todhunter 
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and Lust, 1990). When diagnosing osteoarthritis in a horse, a veterinarian must perform a clinical 
examination to evaluate the horse’s lameness and locate which joint/s are affected. Radiographs 
are important when diagnosing osteoarthritis because they can help eliminate the possible 
presence of fractures and bony prominences. However, radiographs are limiting in the fact that 
they cannot identify early stages of osteoarthritis (McIlwraith, 2003). Nuclear imaging is 
becoming more popular in diagnosing osteoarthritis because it is very sensitive, but has poor 
specificity. In addition to nuclear imaging, computed tomography (CT) and MRIs are being used 
to show early stages of osteoarthritis by looking at subchondral bone changes (McIlwraith, 
2003). Synovial fluid samples can also be tested to evaluate the amount of inflammation in a 
joint. In addition to these diagnostic tools, recent studies have identified biomarkers that can 
detect early degradation of proteoglycans and collagen (the early stages of osteoarthritis) 
(McIlwraith, 2003). Currently, biomarkers are up to 90% accurate.  
Once a horse has been diagnosed osteoarthritic, there are two different approaches for 
managing the disease; (1) return the joint to its normal healthy state as quickly as possible (2) 
prevent the recurrence or reduce the severity of the arthritis (Todhunter and Lust, 1990). The 
principle factor at the top of the inflammatory cascade in horses is interleukin-1 (IL-1), a 
deleterious cytokine, or inflammatory mediator (Farinacci et al., 2009). To slow down the 
inflammation process non-steroidal anti-inflammatory agents, such as phenylbutazone (Bute) and 
flunixin meglumine are commonly used. However, due to the gastrointestinal side effects, 
firocoxib (Equioxx), a specific COX-II inhibitor, is gaining favor (Farinacci et al., 2009). Horses 
can also receive intra-articular corticosteroids, such as methylprednisolone acetate (Depo-
Medrol), triamcinolone acetonide (Vetalog), and betamethasone esters (Celestone). These drugs 
are the most potent in treating osteoarthritis, but due to adverse side effects, such as 
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cardiovascular disease, allergies, dermatitis, gastrointestinal upset, and musculoskeletal 
weakening, they are less preferred. There are also other treatments for acute inflammation and 
joint injuries, which can be used on horses suffering from osteoarthritis, including autologous 
conditioned serum (interleukin-1 receptor antagonist protein- IRAP), and platelet-right plasma 
(Farinacci et al., 2009). Oral nutraceuticals are gaining popularity, although still controversial 
due to lack of evidence. Many in vitro studies have been conducted on glucosamine and 
chondroitin sulfate, but no studies have looked at the safety and therapeutic effects from oral 
joint supplements (McIlwraith, 2003). Due to the lack of scientific evidence and FDA approval 
for oral nutraceuticals, there is little information on dosage, side effects, and health benefits.  
EQUINE GASTROINTESTINAL HEALTH 
In addition to owners commonly using supplements and switching from pharmaceuticals 
to nutraceuticals in canines, it is also becoming popular in the equine industry. Horse owners are 
beginning to use supplements for arthritis in riding horses and performance horses as well as 
supplementing to help avoid gastrointestinal diseases and colic. Gastrointestinal disorders, 
including diarrhea, lesions, enterocolitis, bloat, and colic are very common and can cause 
physiological consequences including death in horses. By supplementing a nutraceutical that can 
suppress proliferation of opportunistic and pathogenic bacteria and control inflammation, equine 
caretakers and owners can help their horses with a majority of disorders that horses commonly 
suffer from.  
Horse Hindgut Overview 
Horses are monogastric animals with a relatively small stomach. From the horse’s mouth 
to their large intestine their gastrointestinal tract is similar to that of a human’s. However, past 
the cecum, a horse’s gastrointestinal tract has more similarities to a cow’s (Hansen et al., 2014). 
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A horse’s gastrointestinal tract can be divided into three segments: foregut, midgut, and hindgut 
(Fraga et al., 2012). The foregut consists of the esophagus and stomach. Once food has passed 
through the stomach, it enters the small intestine (midgut), duodenum, jejunum, and ileum, 
which join the hindgut, cecum, colon, and rectum, at the ilocecal junction. The small intestine 
and stomach can receive a continuous flow of food (Hansen et al., 2014). The cecum is a large 
fermentation vat located on the right side of the animal. Carbohydrates fermented by fibrolytic 
bacteria produce volatile fatty acids (VFAs), which account for 60-70% of the their energy. The 
volatile fatty acids that are yielded during fermentation include acetate, a source of energy for 
tissues, propionate, a precursor for gluconeogenesis, and butyrate, a source of energy for 
colonocytes and helps regulate differentiation of gut epithelia (Hoffman, 2009; Milinovich et al., 
2010; Costa et al., 2012).  
In modern management practices, horse owners and caretakers do not let horses graze 
like they naturally should. In result, caretakers and owners substitute the horse’s diet with grains 
and fats, which the horse cannot properly digest. This unbalanced feeding regimen causes 
numerous digestive disturbances (Hansen et al., 2014).  
Horses are classified as hindgut fermenters, a balance of beneficial and harmful bacteria 
aid in the digestion of foodstuff in the cecum and large intestine (Costa et al., 2012). The hindgut 
is not only a fermentation vat, but it also stimulates immune responses, protects against 
pathogens, production and neutralization of toxins, and gene expression in host epithelial tissues 
(Milinovich et al., 2010). The cecal microbiome is extremely sensitive and can be affected by 
factors like gastrointestinal disease and dietary changes, which can lead to systemic 
consequences and even death (Costa et al., 2012). Therefore, a healthy and balanced microbiota 
is vital for the overall wellbeing of the animal. By understanding external factors and how they 
  
22 
affect the gut microbiota, this could help in diagnosing medical conditions and provide better 
treatment and prognosis of gastrointestinal diseases resulting in colic.   
EQUINE HINDGUT MICROBIOME 
 Gastrointestinal microbiota play an essential role not only in digestion, but also in colonic 
disease (Marteau et al., 2001). Gut microbiome is one of the densest, most dynamic, and 
complex microorganism populations located in the body (Costa et al., 2012). Gut microbes act 
against transient pathogens, aid in digestion and absorption, stimulate the immune system, and 
support enterocytes (Suchodoiski et al., 2012). Gut microbiome population differs between 
species, individuals, and organs (Fraga et al., 2011). It is noted that there are one billion 
microbes within one drop of cecal fluid, consisting of anaerobic microorganisms such as 
bacteria, fungi, protozoa, and archaea (Fraga et al., 2012). If these microbes are changed, this 
could result in gastrointestinal disease and even death. Clostridium perfringens, Clostridium 
difficile, Escherichia coli general and K-12, and Streptococcus bovis/equinus complex (SBEC) 
are common bacteria found in the microbiome of the hindgut. These strains are considered 
opportunistic bacteria, and if the immune system becomes compromised by changes to the 
hindgut microbiome, this will trigger proliferation of harmful and opportunistic bacteria that can 
cause numerous gastrointestinal diseases.  
   The role of the microbes during digestion is fermenting carbohydrates and turning them 
into VFAs (two carbons: acetic, three carbons: propionic, four carbons: butyric, and five carbons: 
valeric). Microbes can digest alpha glucose in the form of starch and beta glucose from crude 
fiber from plant cell walls. When starch is digested by amylase, it is broken down to dextrin, then 
maltose, which is made up of two glucose molecules. Crude fiber is made up of cellulose, 
hemicellulose, and lignin. Cellulose is digested by the microbes, and broken down to insoluble 
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fiber, and produce volatile fatty acids, as a byproduct. Hindgut microbes in the horse only 
produce energy and vitamin B12, while microbes in cattle manufacture B-complex vitamins and 
vitamin K. In general, there are five major types of microbes; cellulolytic bacteria that digest 
fiber, proteolytic bacteria that break down protein, lactic acid-producing bacteria that digest 
starch, protozoa that produce volatile fatty acids, fungi/yeast that breaks down fiber, and other 
bacteria that produce B12-vitamin (Hussein et al., 2004). These five types of microbes are found 
throughout the gastrointestinal tract, but prefer the neutral pH environment of the cecum and 
colon; with cellulolytic bacteria being most abundant in the cecum and colon because that is the 
primary location of fiber digestion (Hussein et al., 2004).  
In literature, gastrointestinal microbiota in general has been the most studied microbiota; 
however, equine microbiota has not been extensively studied (Fraga et al., 2012). In the past, 
equine studies have looked at the microbiota changes during laminitis, identifying and detecting 
lactic acid bacteria (LAB), and bacterial changes during equine grass sickness and foal heat 
diarrhea (Daly et al., 2001). A majority of these studies used fecal samples due to the ease of 
sampling. However, no studies have been conducted on identifying the relationship, short-term 
and long-term, between the cecal and the fecal microbiome in living horses (Daly et al., 2001). 
Even though similar studies have been conducted on humans, dogs, and cattle, data cannot be 
extrapolated to horses due to differences in anatomy, functions, and microbiome composition 
(Schoster et al., 2013). Therefore, only superficial knowledge exists on the equine hindgut 
microbiome due to culturing limitations when identifying bacteria. However, with new 
technological advances and next generation sequencing, scientists can now achieve great strides 
in identifying bacteria down to the genus and species level. 
Clostridium perfringens  
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Clostridium perfringens, formerly known as C. welchii or Bacillus welchii, is a gram-
positive, rod-shaped, anaerobic, spore forming bacterium. The first association C. perfringens 
had with gastrointestinal disease was in the 1920s (Songer, 1996). The next case was post-World 
War 1, in Germany, in the 1940s, when it caused gangrene of the bowel, enteritis necroticans. 
Since then, C. perfringens has been the most commonly associated with gas gangrene (Lawrence 
et al., 1997). In 1950, there was a confirmed food poisoning case that linked back to C. 
perfringens (McDonel, 1986). It was not until the late 1970s that there was a correlation made 
between equine enteric disease and C. perfringens. However, it was not extensively studied until 
1977, when a connection was made between high levels of C. perfringens type A in the feces of 
racehorses suffering from colitis in comparison to the lower levels detected in healthy horses 
(Borriello, 1995). Currently, C. perfringens is associated with causing severe colitis in horses, 
yet can sometimes be ingested without causing any harm. Therefore, it is vital to understand 
what type of strain and toxins are causing gastrointestinal diseases and how to control and 
prevent them. 
C. perfringens, Bacteria (Domain), Firmicutes (Phylum), Clostridia (Class), Clostridiales 
(Order), Clostridiaceae (Family), Clostridium (Genus), C. perfringens (Species), is found in the 
intestinal tract as well as decaying vegetation, marine sediment, and soil (Herholz et al., 1999). 
This bacterium is a mesophile with optimum growing temperatures at 37° C. It is non-motile, but 
has the ability to produce endospores in a short generation time of 6.3 min. C. perfringens has a 
protective thick cell wall made up of peptidoglycans and is a single circular chromosome, 
containing 10 rRNA genes and 96 tRNA genes, made up of approximately 3.6 million base pairs, 
with a guanine-cytosine content ranging from 24-55% (CDC, 2014). Similar to Mycoplasma spp. 
and Bacillus subtills, C. perfringens’ genes are arranged in a specific way that their 
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transcriptional process orients the same directions as their replication direction (CDC, 2014). C. 
perfringens requires essential amino acids from the environment due to its inability to perform its 
own amino acid biosynthesis. However, it can perform anaerobic respiration using nitrates, 
allowing an increased yield of energy. C. perfringens, thrives in little to no oxygen in the 
environment; therefore, it can perform anaerobic fermentation to produce gases such as carbon 
dioxide, to create an anaerobic environment that is optimal for the bacterium to grow and 
survive. The bacterium can carry out glycolysis and glycogenolysis, utilizing simple sugars such 
as glucose. The primary end products of C. perfringens’ metabolisms are ethanol, lactate, 
acetate, butyrate, and carbon dioxide. 
C. perfringens is the most common cause of food borne illness in the United States, with 
a million cases each year (CDC, 2014). C. perfringens is able to produce up to 15 different 
toxins, making it versatile. These toxins are used to isolate the five different types of C. 
perfringens: type A, B, C, D, and E. The four toxins that are primarily used to isolate the 
different types include alpha, beta, epsilon, and iota-toxins. Type A is the most common and 
most variable, and subdivided into enterotoxigenic and non-enterotoxigenic strains (Herholz et 
al., 1999). Enterotoxigenic type A and C are associated with equine enterocolitis, gas gangrene, 
infections, avian and canine necrotic enteritis, colitis in horses, and diarrhea in pigs (Divers and 
Ball, 1996). Types B, C, D, and E can cause severe enteritis, dysentery, toxemia, and high 
mortality rates in young lambs, calves, pigs, and foals. Types B, C, D, and E have been 
intermittently associated with foal enterocolitis, and equine antibiotic associated diarrhea (Divers 
and Ball, 1996). Even though the alpha toxin is noted to be relatively nonpathogenic, the beta2 
toxin plays a significant role in digestive disease, specifically, enterocolitis in equine (Herholz et 
al., 1999). This is mainly due to the C. perfringens enterotoxin (CPE); the main virulence factor 
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that initiates many critical gastrointestinal diseases across species (Herholz et al. 1999). CPE 
works in a four-step mechanism against membrane action (CDC, 2014). First, CPE binds to the 
target receptors on plasma membrane protein or claudin protein, which leads to the formation of 
a small complex. This changes the anatomical structure of the intestinal tissue due to binding to 
claudins, proteins that maintain tight junction integrity and establishment of paracellular barriers. 
These barriers control the flow of molecules between the cells of the gastric epithelium (Herholz 
et al. 1999; CDC, 2014). Secondly, the complex undergoes physical changes when it binds to 
other membrane proteins, forming a larger complex in the membrane. Thirdly, this results in the 
disruption of the membrane’s permeability, leading to cell death due to the osmotic equilibrium 
not being maintained (CDC, 2014). As the CPE in the intestinal lumen increases, more deaths of 
pathways are triggered (Chakrabarti et al., 2003). Lastly, the CPE is capable of forming a larger 
complex in the membrane and its toxic levels are enhanced when the first 45-N terminal amino 
acids are eliminated (Herholz et al., 1999). This contributes to intestinal fluid and electrolytes 
being lost through diarrhea (McClane, 2000). It has also been noted that high levels of CPE can 
have a pro-inflammatory effect, which can worsen the diarrhea symptoms (Chakrabarti et al., 
2003). In a recent study, C. perfringens enterotoxins were detected in 19% of adult horses and 
28.6% of foals with diarrhea symptoms, in contrast to not being detected in healthy horses 
(Herholz et al., 1999). Due to the increased interest of horse enterocolitis, CPE, and beta2 toxins, 
many studies have looked at C. perfringens enterotoxin in horses with diarrhea; yet it needs to be 
further investigated to identify types, strains, toxins, and how to prevent related gastrointestinal 
diseases.   
Clostridium difficile 
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 Clostridium difficile, formerly named Bacillus difficilis, due to how difficult it was to 
isolate and cultivate was first isolated from newborn infants in 1935 (Hall and O’Toole, 1935). It 
was not until 1970, that a correlation was identified between C. difficile and humans with colitis 
(Ehrich et al., 1984). The first time C. difficile was identified in mature horses, located in the 
Potomac River area, with diarrhea was in 1984. Cases of C. difficile colitis in horses treated with 
antimicrobials increased in 1993. Since then, many studies have examined horses with diarrhea 
associated with the presence of C. difficile (Baverud et al., 1997).  
 C. difficile, Bacteria (Domain), Firmicutes (Phylum), Clostridia (Class), Clostridiales 
(Order), Clostridiaceae (Family), Clostridium (Genus), C. difficile (Species), is a large gram-
positive, anaerobic, spore-forming, motile, rod bacteria. C. difficile is associated with colitis and 
diarrhea, especially in horses (Divers and Ball, 1996). This bacterium requires five amino acids 
for energy metabolism, (leucine, lysine, proline, tryptophan, and valine) and an addition of 
glycine has been shown to increase growth. To generate energy in the form of ATP, C. difficile 
utilizes amino acid fermentation and simple sugars such as glucose (Kim et al., 1981). The 
primary fermentation end product of C. difficile is acetic, iso-butyric, iso-valeric, valeric, and 
iso-carproic acid.  
 C. difficile is one of the top three most common bacteria linked to diarrhea. In the United 
States it contributes to 14,000 human deaths each year and contributes to 20-30% of acute 
diarrhea cases in equine (CDC, 2014). C. difficile is also directly linked to equine gastrointestinal 
inflammatory diseases, such as enterocolitis. C. difficile produces protein toxins A, B, and/or 
binary toxin CDT in the intestine (Divers and Ball, 1996). Protein toxin A is an enterotoxin that 
causes hyper section of the fluid into the intestinal lumen and can cause tissue damage. Protein 
toxin B is a potent cytotoxin that induces inflammation and necrosis. Lastly, protein toxin CDT 
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is still relatively unstudied and little is known about it (Divers and Ball, 1996). Typically, C. 
difficile has a low transient level in healthy horses. Due to the opportunistic properties of C. 
difficile, when the healthy microflora are compromised, this allows the C. difficile spores to 
travel down the gastrointestinal tract without being affected by the gastric acid barrier; resulting 
in rapid multiplying of the bacterium in the colon. This overgrow of bacteria in the intestines is a 
precursor for many gastrointestinal diseases (Divers and Ball, 1996). Compromised immune 
systems can from antineoplastic, immunosuppressive, and antimicrobial treatments or stress. In 
horses, stress can be caused by dietary changes, including the addition of a new supplement, 
environmental changes, transportation, starvation, surgery, and other medical treatments (Divers 
and Ball, 1996). In humans, the pathogenesis is fecal-oral route; however, in horses it has still yet 
to be identified. Clinical symptoms of C. difficile can vary, but may include abdominal pain, 
diarrhea with or without blood, abdominal distention, dehydration, toxemia, and shock (Divers 
and Ball, 1996). If an outbreak occurs, proper isolation and disinfecting with sporicidal 
disinfectants are ideal.  
 Identifying and culturing C. difficile is difficult because the toxin type must also be 
identified. In 1979, a medium called cycloserine-cefoxitin-fructose agar (CCFA)-selective was 
developed. Once fecal samples were collected, they were streaked onto selective and differential 
medium to help identify toxin types. Also, different additives were tested for culturing C. 
difficile, including horse serum, sodium taurocholate, and media with mannitol replacing fructose 
(Dezfulian et al., 1981). Further modifications have been made for cycloserine and cefoxitin for 
an ideal media. C. difficile can also be tested by cytotoxicity assays, ELISA tests, and microwell 
enzyme immunoassays (EIA) that are toxin specific, for fecal samples (CDC, 2014). Lastly, 
anaerobic cultures can be tested by PCR to determine if it is a toxigenic or a non-toxigenic strain 
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(Divers and Ball, 1996). In horses, it is important to test for the presence, but also the type of 
toxin. Due to the numerous tests for identifying toxins along with the variation in degree to 
which toxins are produced between equine isolates, it is important to take multiple samples over 
time to avoid false negatives in horses (Bårerud et al., 2003). Overall, horses have some level of 
C. difficile in their hindgut (0%-7.59%), depending on the study, and are considered carriers; 
therefore, it is important to be mindful of these percentages when analyzing a microbial sample 
(Bårerud et al., 2003).  
Escherichia coli 
 Escherichia coli is the most prevalent infecting organism in the family of gram-negative 
bacteria known as enterobacteriaceae. E. coli was first discovered in the human colon in 1885, by 
German bacteriologist, Theodor Escherich. Escherich also showed that certain strains of E. coli 
were associated with infant diarrhea and gastroenteritis. E. coli was initially named bacterium 
coli, but was later changed to Escherichia coli in honor of its discoverer (CDC, 2014; EPA, 
2014). In the 1960s and 1970s, mass amounts of information were discovered about E. coli. The 
need for information about this bacterium came from the affordable and quick methods that 
became available to identify enteric bacteria and the major shift in nosocomial infections from 
gram-positive to gram-negative (EPA, 2014). E.coli is referred to as the best and most-studied, 
free-living organism and is noted to have over 700 serotypes identified (Bertone et al., 1990). By 
studying the “O” and “H” antigens on the bacteria and the flagella, scientists can help distinguish 
between the different serotypes (Bertone et al., 1990).  
 E. coli, Bacteria (Domain), Proteobacteria (Phylum), Gammaproteobacteria (Class), 
Enterobacteriales (Order), Enterobacteriaceae (Family), Escherichia (Genus), coli (Species), is a 
gram-negative, facultative anaerobic, rod-shaped bacterium, with optimum growing temperatures 
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at 37° C. This bacterium is commonly found in the lower intestines of warm-blooded animals. E. 
coli makes up about 0.1% of gut microbes and most strains are harmless. Some strains are part of 
the normal gut microbiome, produce vitamin K2, and prevent colonization of the intestine with 
pathogenic bacteria (CDC, 2014). E. coli makes ATP by aerobic respiration, if oxygen is present, 
but can switch to fermentation or anaerobic respiration if oxygen is limited or absent. The end 
product of fermentation is lactate, succinate, ethanol, acetate, and carbon dioxide (CDC, 2014; 
EPA, 2014). 
 Even though E. coli normally lives in the intestines, and most strains are harmless, some 
strains can cause diarrhea. This bacterium is also responsible for numerous reports of 
contaminated food and beverages (Bertone et al., 1990). The most widely known strain, E. coli 
0157:H7, produces a toxin called shiga toxin, which is identical to the shigella dysenteria type 1 
bacteria. E. coli 0157:H7 is known for causing over 100,000 illnesses, 3,000 hospitalizations, 
and 90 deaths, annually, in the United States (CDC, 2014). The incubation period is, typically, 3-
4 days, but can range anywhere from one to ten days. Once inoculated with the bacterium, it 
rapidly multiplies in the large intestine and then binds tightly to cells in the intestinal lining. 
From there, it attaches to receptors on white blood cells and is transferred all over, resulting in 
inflammation due to hemorrhagic colitis with abdominal pains, severe cramps, and diarrhea 
(Bertone et al., 1990). Rarely, E. coli can cause bowel necrosis and perforation without 
progressing to hemolytic uremic syndrome (HUS). In humans, the pathogenesis of E. coli is 
fecal-oral route (CDC, 2014).  
 One of the many serotypes of E. coli, is E.coli K-12. E. coli K-12 is a descendant isolate 
used commonly in molecular biology as a model organism and in broths. E. coli K-12 was first 
isolated in 1920, by the Lister Institute in London. In 1922, at Stanford University, the strain was 
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isolated from a stool sample from a patient with diphtheria (CDC, 2014). Charles E. Clifton, in 
the 1940s, used E. coli K-12 to study nitrogen metabolism, which then deposited it in the ATCC 
and lent it to Edward Tatum for his study in tryptophan biosynthesis (CDC, 2014). Different 
strains of K-12 have developed by treating E. coli K-12 with agents such as nitrogen, mustard, 
ultra-violet radiation, and x-rays (Bertone et al., 1990). Currently, a study showed that curcumin-
converting microorganisms were isolated from human feces and had a high activity level to E. 
coli, specifically E. coli K-12, substrain DH10B (Hassaniansab et al., 2010). In the study, 
researchers observed that E. coli was able to act on curcumin by using a two-step reduction 
process. Curcumin was being converted, NADPH-dependently, into an intermediate product, 
dihydrocurcumin, and then the end product, tetrahydrocurcumin (Hassaniansab et al., 2010). The 
“NADPH-dependent curcumin/dihydrocurcumin reductase” was called CurA (Hassaniansab et 
al., 2010). Due to its recent discovery in humans, little is known about CurA, as a whole, and in 
other species.  
Streptococcus bovis/equinus complex 
Streptoccocus bovis/equinus complex (SBEC) is a heterogeneous group within the 
Lancefield group D streptococci. The genus, Streptococcus, is gram-positive, aerobic cocci, 
lactic acid bacterium (LAB) that belongs to the phylum Firmicutes (Hastie et al., 2008). Most 
Streptococcus genomes are 1.8-2.3 megabase pairs in sizes and can encode 1,700 to 2,300 
proteins. In 1984, Streptococcus was split into two genera, Enterococcus and Lactococcus and 
can be found in the microbiomes of the mouth, skin, intestine, and upper respiratory tract. 
Different species of Streptococcus can be classified by their hemolytic properties on blood agar: 
alpha-hemolytic, green hemolysis zones; beta-hemolytic, clear hemolysis zones; gamma-
hemolytic, no hemolysis zones (Hastie et al., 2008). Alpha-hemolytic species such as S. 
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pneuomniae and S. virdans, cause oxidation of iron within red blood cells. Beta-hemolytic 
species completely rupture red blood cells. Lastly, gamma-hemolytic species cause no 
hemolysis. SBEC is classified as a Lancefield group D (enterococci) beta-hemolytic species, 
which can cause many infections in species such as cattle and horses.  
Streptococci have been divided into six groups based on their 16S rDNA sequence, which 
is why Streptococcus bovis and Streptococcus equinus are considered a complex; with only 15 
base pairs different, most labs will report them as a group, while other labs will classify them 
down to their subspecies level by conducting a follow-up fermentation study (Jans et al., 2011). 
However, the subspecies in this complex differ in their microbiology, pathogenesis, and 
epidemiology (Jans et al., 2011). Some of the species in this complex are pathogenic and can 
have detrimental tolls on the fermentation process of the equine hindgut and cause lesions in the 
colon (Jans et al., 2011). SBEC is also known for diseases, such as meningitis, neonatal sepsis, 
peritonitis, ruminal acidosis, feedlot bloat, septic arthritis, and vertebral osteomyelitis (Jans et al., 
2011). The diseases caused by Streptococci are heightened by their virulence factors, including 
streptolysin, DNAases, and hyaluronidase (Hastie et al., 2008). Some strains also release 
exotoxins that activate T-cells, which trigger the release of cytokines. The released cytokines 
activate detrimental physiological processes, such as coagulation, inflammation, shock, organ 
failure, and death (Hastie et al., 2008). 
In hindgut fermenters, such as horses, a diet high in starch or sugar can promote 
proliferation of SBEC. As a lactic acid bacterium, the fermentation of these carbohydrates to 
lactic acid can cause a decrease in pH, which can lead to acidosis, bloat, starch-induced colic, 
and other gastrointestinal conditions. Therefore, it is important to manage a horse’s diet, but to 
also control the concentration of SBEC in the hindgut.  
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CONCLUSION 
In summary, nutraceuticals, especially turmeric and its active ingredient, curcumin, are 
increasing in popularity in veterinary medicine due to it being relatively inexpensive and 
minimal to no side effects. Turmeric is used as an anti-inflammatory, stimulant, aspirant, 
carminative, astringent, detergent, and diuretic (Li et al., 2011). Curcumin, the major component 
and active ingredient of turmeric, has been used for thousands of years in Eastern medicine. 
However, only recently have the biological actions of curcumin been examined (Jagetia and 
Aggarwal, 2007; Wynn and Fougere, 2008). In clinical trials, it has been reported that curcumin 
may have an anti-cancer effect, in the form of a chemoprevention agent (Li et al., 2011). 
Throughout multiple studies on a variety of species, curcumin has potential for being a 
therapeutic agent in inflammatory diseases, including inflammatory bowel disease, pancreatitis, 
and arthritis (Jagetia and Aggarwal, 2007; Wynn and Fougere, 2008; Li et al., 2011). Curcumin 
is also known to have antimicrobial properties. Turmeric and curcumin, with their anti-
inflammatory and antimicrobial properties, have potential to alleviate arthritic symptoms in 
canines and equines as well as controlling colic and gastrointestinal upset by reducing 
opportunistic and harmful bacteria proliferation. 
In a four-part study, the first part will evaluate the therapeutic efficacy and safety of 95% 
curcumin (500 mg, SID) and 95% liposomal-curcumin (250 mg, BID) in ten moderately arthritic 
dogs. The objective of this study was to compare the two groups, given either curcumin or 
liposomal-curcumin, to determine which form of the nutraceutical alleviates symptoms better in 
moderately arthritic dogs. As a follow up study, the second study evaluated the therapeutic 
efficacy and safety of 95% curcumin, 100 mg or 500 mg, SID, in ten moderately arthritic dogs. 
The objective of this study was to compare the two groups, given either 100 mg or 500 mg of 
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95% curcumin, to determine which dosage of the nutraceutical improves the symptoms and 
ROM in moderately arthritic canines more.  
In project three, the species will transition to equine. Project three consists of a two in 
vitro, closed-system, batch culture studies looked at the effects of 95% turmeric, 95% curcumin, 
and 95% liposomal-curcumin on five opportunistic strains of bacteria found in the equine 
hindgut. The objective of this study was to assess the effects of the different forms of the 
nutraceutical, used in the previous studies, on bacteria in the equine hindgut. A follow-up in vitro 
study was conducted looking at different dosages of 95% liposomal-curcumin, the nutraceutical 
that had the greatest reduction in the five opportunistic bacteria in the first in vitro study. The 
results from the third study were used for the fourth and final study, based on which form of the 
nutraceutical, 95% turmeric, 95% curcumin, or 95% liposomal-curcumin, had the greatest 
overall effect on the hindgut bacteria. The fourth study was a repeat of the second in vitro study 
except taking in vivo with dosages of 15 g, 25 g, and 35 g, and looking at the anti-inflammatory 
properties in addition to the antimicrobial properties of liposomal-curcumin. This study looked at 
therapeutic and safety effects of liposomal-curcumin at three different dosages because there has 
yet to be an approved dose of orally administered curcumin in equines. By conducting these 
studies, we hope to gain information about turmeric, curcumin, and liposomal-curcumin in 
relationship to its dosage, therapeutic efficacy, safety, and effects on gut microbes and 
inflammation conditions.  
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Figure 1.1. Chemical structures of turmeric, curcumin, and its derivatives   
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Table 1.1. Maximum joint motion in canine (Millis, 2004, p. 536) 
 
Joint Extension Flexion 
Shoulder 142 degrees-ground 125 degrees-ground 
Elbow 124 degrees-ground 98 degrees-ground 
Carpus 124 degrees-ground 97 degrees-ground 
Hip 141 degrees-ground 115 degrees-ground 
Stifle 141 degrees-ground 109 degrees-ground 
Hock 135 degrees-ground 115 degrees-ground 
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Table 1.2. Erythrocyte sedimentation rate for small domestic animals, mm/hr (Provet, 2014) 
 
Species Normal Range  
Canine 0-5 
Feline 0-12 
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Table 1.3. Erythrocyte sedimentation rate for equine, mm/hr (Blair Street Vet Hospital, 2014) 
 
Packed Cell Volume Normal Range  
35 13-43 
37 8-28 
39 3-9 
40 0-8 
45 0-3 
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CHAPTER 2 
THERAPEUTIC AND SAFETY EVALUATION OF CURCUMIN AND LIPOSOMAL-
CURCUMIN IN MODERATELY ARTHRITIC DOGS 
ABSTRACT: 
The objective of this investigation was to evaluate the efficacy and safety of 95% 
curcumin and 95% liposomal-curcumin in moderately arthritic dogs. Ten client-owned dogs in a 
randomized, double-blinded study received either 95% curcumin (500 mg) once a day (SID) or 
95% curcumin (250 mg) twice a day (BID) for a period of five months. Dogs were evaluated 
each month for physical condition (body weight, body temperature, heart rate, and respiratory 
rate), pain associated with arthritis (overall pain, pain from limb manipulation, and pain after 
physical exertion), and range of motion was measured using a goniometer on the stifle, shoulder, 
and elbow joints. Serum samples collected from these dogs were examined each month for 
biomarkers of liver (total bilirubin, ALT, and AST), kidney (BUN and creatinine), heart and 
muscle (creatine kinase) functions. The findings of this study revealed that dogs receiving 95% 
curcumin (Group-I) and 95% liposomal-curcumin had a significant (P < 0.05) reduction in pain 
from limb manipulation by day 150. Group-1 had a significant reduction in overall pain by day 
60 and Group-II had a significant reduction in overall pain by day 90. Group-I had a significant 
reduction in pain after physical exertion by day 90 and Group-II had significant reduction in pain 
after physical exertion on day 150. Dogs in either group showed no significant changes (P > 
0.05) in physical parameters or serum markers, suggesting that both 95% curcumin and 95% 
liposomal-curcumin were well tolerated by moderately arthritic dogs. It was concluded that both 
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95% curcumin and 95% liposomal-curcumin significantly (P < 0.05) reduced pain in 
osteoarthritic dogs and markedly improved their daily life activity without any side effects.  
INTRODUCTION 
Arthritis is a commonly occurring chronic illness in human and animals (Gupta et al., 
2009). Among all domestic and pet animal species, dogs and horses suffer from arthritis more 
often because of excessive running or exercise, injury, and/or genetic predisposition. Presently, 
one in four of 77.2 million pet dogs in the United States are diagnosed with some form of 
arthritis (Lawley et al., 2013). In dogs, osteoarthritis is more common than rheumatoid arthritis 
and pain is the number one observation. Osteoarthritis, also known as degenerative joint disease 
(DJD), is a slowly progressive inflammatory disease. Osteoarthritis is characterized by 
degeneration of the cartilage, hypertrophy of bone at the margins, and changes in the synovial 
membrane, and that eventually results in pain and stiffness of joints (Reid and Miller, 2008). 
Alterations in joint structures can decrease flexibility, and lead to severe pain due to lack of 
hydration and inflammation. Cells within the damaged joints release pro-inflammatory 
cytokines, which further the inflammatory process (Reid and Miller, 2008). This causes more 
breakdown of the cartilage collagen type II and proteoglycans. This perpetuating destructive 
cycle ultimately results in cartilage destruction, subchondral bone thickening, and synovial 
membrane inflammation (Renberg, 2005). 
         Currently, osteoarthritis is treated or managed by invasive as well as noninvasive means. In 
the recent past, the treatment options for arthritis were typically non-steroidal anti-inflammatory 
drugs (NSAIDs) given alone or in combination with other disease-modifying agents. NSAIDs 
(COX enzymes inhibitors) eliminate pain, but do not eliminate the signs and symptoms of active 
disease nor do they repair cartilage (Vaughn-Scott, et al., 1997). In recent years, chronic use of 
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NSAIDs has been linked to numerous side effects, including gastrointestinal (GI) bleeding, and 
renal and hepatic dysfunction. Anti-inflammatory drugs such as aspirin and ibuprofen are non-
specific inhibitors of COX enzymes (COX-I and COX-II) (Vaughn-Scott, et al., 1997). They 
inhibit the production of inflammatory prostaglandins, resulting in their therapeutic effect, but 
also inhibit the production of constitutive prostaglandins, resulting in side effects, such as GI 
bleeding. Therefore, under these circumstances, a safe therapy is warranted for arthritic dogs. 
Herbal medicine is increasing its popularity in veterinary medicine due to it being 
relatively inexpensive and minimal to no side effects. Herbal medicine is becoming a common 
treatment for mastitis, foot-and-mouth disease, skin allergies, food poisoning, tympany, and 
expulsion of placenta (Chan et al., 2009). In the past, nutraceuticals were a common therapy for 
livestock in treating a variety of diseases including hepatitis, chronic heart disease, skin 
disorders, wounds, and arthritis (Mahima et al., 2013). According to past studies, particular 
nutraceuticals can possibly affect the progression of arthritis by preventing degradation and 
enhancing the repair of joint cartilage (Sanghi et al., 2008).   
 Turmeric is a rhizomatous herbaceous perennial plant, Curcuma longa Linn, belonging to 
the ginger family, Zingiberaceae (Chan et al., 2009). Turmeric is native to southeast India and 
grows in temperatures between 20-30° C, with high amounts of rainfall. Once picked, the 
rhizomes are boiled, dehydrated, and then ground into orange-yellow powder, which is used for 
curries, dyeing, and mustard condiments (Prasad et al., 2011). Turmeric is one of the oldest 
sources of spice, coloring pigments, and medicine, dating back to 1900 B.C. (Hassaninasab et al., 
2010).  
Out of all Curcuma longa Linn species, Curcuma longa is the most chemically 
investigated (Li et al., 2011). Curcuminoids, belonging to the diarylheptanoid group, are the most 
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important chemical components of turmeric and are the main active ingredient in turmeric. This 
group makes up roughly 2-6% of the spice, with curcumin as the main compound (Wynn and 
Fougere, 2008). Three main curcuminoids observed in commercial supplements are curcumin 
(curcumin I), demethoxycurcumin (curcumin II), and bis-demethoxycurcumin (curcumin III). 
Typical commercial products contain 77% curcumin, 17% demethoxycurcumin, and 3% bis-
demethoxycurcumin. These curcuminoids are said to work synergistically (Jagetia and 
Aggarwal, 2007; Wynn and Fougere, 2008). Commercial curcumin, it is often 95% curcumin 
instead of 100% because there is not an increase of bioavailability from 95% to 100% and it 
costs less to manufacture (Wynn and Fougere, 2008). The bioavailability of curcumin is noted to 
be minimal due to its hydrophobic and low intrinsic activity, poor absorption, and high rate of 
metabolism and elimination from the body (Anard et al., 2009). However, curcumin can be 
encapsulated into liposomes, liposomal curcumin, to increase bioavailability (Li et al., 2007; Li 
et al., 2011). Liposomes can carry both hydrophobic and hydrophilic molecules, which make 
them ideal for drug delivery (Anard et al., 2009).  
In Ayurvedic medicine, turmeric is used as an anti-inflammatory, and in Chinese 
medicine, used as stimulant, aspirant, carminative, astringent, detergent, and diuretic (Li et al., 
2011). Curcumin has been used for thousands of years in Eastern medicine. However, only in 
recent studies has the biological action of curcumin have been examined (Jagetia and Aggarwal, 
2007; Wynn and Fougere, 2008). Throughout multiple studies on a variety of mammalian 
species, curcumin has potential for being a therapeutic agent in inflammatory diseases, including 
inflammatory bowel disease, pancreatitis, and arthritis (Li et al., 2011). Therefore, this is 
important to note that dogs suffering from osteoarthritis could potential be given curcumin over 
NSAIDs to help alleviate symptoms, without the negative side effects. In the present 
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investigation, curcumin was evaluated for its therapeutic and safety evaluation in osteoarthritic 
dogs.  
MATERIALS AND METHODS 
Animals 
 Ten client-owned moderately arthritic dogs, weighing between 40-65 pounds, 10 ± 2 
years, were used in this study. These dogs, based on signs of joint stiffness, lameness, degree of 
range of motion, had pain at the level of moderate arthritis (>2 on a 4-point scale). My inclusion 
criteria of dogs in this study excluded those having any concurrent diseases (liver, kidney, or 
heart disease, neoplasia, cancer or any other major disease) and were heartworm negative. 
Institutional Animal Care and Use Committee (IACUC) approval and owner’s consent were 
obtained prior to the initiation of this study. 
Experimental Design 
 In a randomized double-blind study, ten client-owned dogs, divided into two groups (n = 
5), received 95% curcumin (500 mg) once a day (Group-I) or 95% liposomal-curcumin (250 mg) 
twice a day (Group-II). The study was carried out for a period of five months at Murray State 
University. None of the dogs received any treatment or supplements for four weeks prior to the 
study or during the study period.   
Pain Measurement 
 At pre-determined intervals (i.e. 30 days), each dog was evaluated for overall pain, pain 
upon manipulation, and pain after physical exertion, for a period of five months. Overall pain, on 
a scale of 0-10, was graded as: 0, no pain: 2.5, mild pain: 5, moderate pain: 7.5, severe pain: 10, 
severe and constant pain. Pain after manipulation, on a scale of 0-4, was evaluated as: 0, no pain: 
1, mild pain: 2, moderate pain: 3, severe pain: 4, severe and constant pain. Pain after physical 
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exertion, on a scale of 0-4, was evaluated as: no pain: 0, no pain: 1, mild pain: 2, moderate pain: 
3, severe pain: 4, severe and constant pain. Range of motion was evaluated with a goniometer 
and the degree of motion during flexion was noted. The physical examination of each limb 
started with the forelimbs and ended with the hind limbs. The evaluation focused on 
manipulation of the limbs in a forward, backward, and circular motion. Three main joints in each 
dog were evaluated, including shoulder joint, elbow joint, and stifle joint. Popping and cracking 
of the joints as well as vocal pain were noted for each canine. Detailed criteria of the 
measurement of pain are provided in our earlier publications (Deparle et al., 2005; D'Altilio et 
al., 2007; Peal et al., 2007; Gupta et al., 2009; Gupta et al., 2011; Fleck et al., 2013; Lawley et 
al., 2013). The present investigation was carried out on moderately arthritic dogs. A moderately 
arthritic dog exhibits overall pain of about a 5 on a scale of 0-10; pain upon limb manipulation 
about a 2 on a scale of 0-4; and pain after physical exertion about a 2 on a scale of 0-4. 
Physical Examination 
 On a monthly basis, dogs were given a full physical examination for body weight, body 
temperature, heart rate, and respiratory rate (Table 2.1).  
Serum Biomarkers Assays 
 Blood samples were collected from the cephalic vein using a 3 mL syringe with a 22-
gauge, 1-inch needle and were stored in a marble top tube and lavender top tube. Samples in the 
marble top tubes were then spun to collect serum and transferred to a red top tube for evaluation. 
Serum samples were collected each month and analyzed for liver (total bilirubin, ALT, and 
AST), kidney (BUN and creatinine), heart and muscle (CK) functions, using a Beckman AU 480 
serum analyzer. The lavender top tubes were analyzed for a complete blood count including a 
five-part differential (neutrophils, lymphocytes, monocytes, eosinophils, and basophils). Whole 
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blood stored in lavender top tubes was collected each month to analyze effects on red blood cells 
and white blood cells. The serum and whole blood sample assays indicated that neither 95% 
curcumin nor 95% liposomal-curcumin produced adverse effects in vital organs of arthritic dogs.  
Statistical Analysis 
 The data presented are means ± SEM. Statistical significance of difference comparing 
each month against baseline (day 0) was determined by analysis of variance (ANOVA) coupled 
with Tukey-Kramer post-hoc test (P < 0.05) using the Statistical Analysis and Graphics Software 
for Windows (NCSS9). 
RESULTS 
 On a monthly basis, each dog was examined for pain level (overall pain (Figure 2.2), pain 
after limb manipulation (Figure 2.3), and pain after physical exertion (Figure 2.4) While 
evaluating overall pain, the key points were to observe the dog’s gait, joint range of motion, 
ability to sit or lie down, ability to rise from a sitting position and from a lying position. Group-I 
dogs receiving 95% curcumin (500 mg, SID), showed significant (P = 0.01) reduction in overall 
pain by day 60 (4.8 ± 0.34) compared to day 0 (6.6 ± 0.51). The maximum reduction in overall 
pain was noted on day 150 (1.9 ± 0.18). Group II dogs receiving 95% liposomal-curcumin (250 
mg, BID), showed significant (P = 0.02) reduction in overall pain by day 90 (4.1 ± 0.24) 
compared to day 0 (7.2 ± 0.66). The maximum reduction in overall pain was noted on day 150 
(2.9 ± 0.6). 
 Pain after limb manipulation was measured in each limb of the dog for flexibility, joint 
integrity, and vocalization. The pain level was significantly reduced by day 150 in both groups, 
Group-I (0.4 ± 0.3) and Group-II (0.6 ± 0.29). The canines were evaluated for pain after two 
minutes of jogging. After jogging, pain level was assessed based on the dog’s body position, 
  
46 
limping, flexibility, and vocalization. Group-I had noted significant reduction in pain after 
physical exertion on day 90 (0.2 ± 0.2) and day 150 (0.2 ± 0.2). Group-II had significant 
reduction in pain after physical exertion only on day 150 (0.5 ± 0.5).  
 Data of physical parameters (body weight, body temperature, heart rate, and respiratory 
rate) were not significantly different (Table 2.1). Dogs receiving 95% curcumin or 95% 
liposomal-curcumin had no significant change in any physical parameters. Dogs receiving 95% 
curcumin or 95% liposomal-curcumin had no significant change in serum biomarkers during the 
study of 150 days (Table 2.4). 
DISCUSSION 
 In the present paper, we report that 95% curcumin or 95% liposomal curcumin at a dose 
of 500 mg is effective in reducing arthritic pain and enhancing the daily activity of dogs without 
exerting any side effects. Curcumin and liposomal-curcumin administration ameliorated arthritic 
pain in all three categories (overall pain, pain after limb manipulation, and pain after physical 
exertion) with maximum effect noted on day 150. Curcumin, the active ingredient in turmeric, is 
known for its medicinal properties, including anti-inflammatory, antioxidant, antimicrobial, 
wound healing, and anti-tumor properties (Zhu et al., 2014). Curcumin, has been used both for 
preventative health and for treating many diseases such as bowel disease, pancreatitis, skin, 
pulmonary, gastrointestinal, and aches, pains, wounds, sprains, liver disorders, and cancer for 
thousands of years. Since curcumin has multiple medicinal benefits, it is highly likely that it 
reduced the arthritic pain due to a variety of pharmacological mechanisms, including anti-
inflammatory and antioxidant properties.   
              In conclusion, curcumin is an all-natural supplement, which offers significant anti-
arthritic properties including reduction of pain and inflammation and increasing joint range of 
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motion. On average, dogs experienced significant increase in ROM and decrease in pain 60-90 
days after beginning the treatment. All dogs responded well to curcumin administration without 
exhibiting any adverse effects, thereby giving this supplement an edge over many other anti-
arthritic nutraceuticals and pharmaceuticals. Further work needs to be conducted examining 
curcumin’s anti-inflammatory properties in dogs on the same diet and exercise regime.  
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Figure 2.1. Chemical structures of curcumin I, II, and III 
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Figure 2.2. Effects of (Group I) 95% curcumin (500 mg, SID) or (Group II) 95% liposomal-
curcumin (250 mg, BID) on overall pain in moderately arthritic dogs.  
Overall pain was graded on a scale of 0-10 (0, no pain: 2.5, mild pain: 5, moderate pain: 7.5, 
severe pain: 10, severe and constant pain).  
*Significantly different compared to Day 0 (P < 0.05) 
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Figure 2.3. Effects of (Group I) 95% curcumin (500 mg, SID) or (Group II) 95% liposomal- 
curcumin (250 mg, BID) on pain from limb manipulation in moderately arthritic dogs. 
Pain from limb manipulation was graded on a scale of 0-4 (0, no pain: 1, mild pain: 2, moderate 
pain: 3, severe pain: 4, severe and constant pain). 
*Significantly different compared to Day 0 (P < 0.05)  
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Figure 2.4. Effects of (Group I) 95% curcumin (500 mg, SID) or (Group II) 95% liposomal-
curcumin (250 mg, BID) on pain after physical exertion in moderately arthritic dogs.  
Pain from limb manipulation was graded on a scale of 0-4 (0, no pain: 1, mild pain: 2, moderate 
pain: 3, severe pain: 4, severe and constant pain). 
*Significantly different compared to Day 0 (P < 0.05) 
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Table 2.1. Effects of curcumin on physical parameters in osteoarthritic dogs 
 
*Significantly different compared to Day 0 (P < 0.05) 
 
Parameters Group Day 0 Day 30 Day 60 Day 90 Day 120 Day 150 
Body Weight 
(lbs) 
 
 
 
 
I 
52.50 ± 
5.82 
49.70± 
5.48 
51.20± 
5.41 
50.16± 
5.51 
50.64± 
4.62 
49.04± 
5.44 
II 
57.80 ± 
10.05 
58.90± 
9.93 
58.50± 
10.53 
53.92± 
9.05 
56.04± 
9.38 
57.68± 
7.86 
Temperature 
(°F) 
 
Normal range: 
101-102.5°F 
 
 
I 
100.00± 
0.49 
101.70± 
0.29 
101.02± 
0.18 
100.86± 
0.23 
100.28± 
0.37 
100.12± 
0.15 
II 
99.86± 
0.53 
101.12± 
0.18 
101.16± 
0.20 
100.86± 
0.42 
100.40± 
0.39 
100.90± 
0.15 
Heart Rate 
(bpm) 
 
Normal range: 
70-160 bpm 
 
 
I 
118.80± 
12.21 
118.80± 
6.68 
116.40± 
14.89 
118.40± 
16.40 
133.20± 
13.47 
108.80± 
13.96 
II 
9.63± 
0.87 
9.53± 
1.16 
9.86± 
1.05 
10.23± 
0.85 
10.97± 
1.33 
10.30± 
1.09 
Respiratory 
Rate 
(bpm) 
 
Normal range: 
10-35 bpm 
 
I 
18.67± 
0.67 
24.67± 
2.91 
24.50± 
2.06 
22.00± 
2.28 
24.60± 
2.94 
23.20± 
2.06 
II 
20.50± 
1.26 
20.67± 
1.76 
20.66± 
1.76 
21.50± 
1.50 
20.20± 
2.58 
20.00± 
2.02 
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Table 2.2. Effects of curcumin on arthritis associated pain level in osteoarthritic dogs 
*Significantly different compared to Day 0 (P < 0.05) 
Parameters Group Day 0 Day 30 Day 60 Day 90 Day 120 Day 150 
Overall Pain 
Score (0-10) 
 
 
 
 
I 
6.60± 
0.51 
5.50 ± 
0.45 
4.80± 
0.34* 
3.60± 
0.24* 
2.20± 
0.40* 
1.90± 
0.18* 
II 
7.20± 
0.66 
6.20± 
0.64 
5.20± 
0.43 
4.10± 
0.24* 
2.70± 
0.30* 
2.90± 
0.60* 
Pain Severity 
Score (0-4) 
 
 
 
 
I 
2.90± 
0.15 
2.05± 
0.23 
1.85± 
0.34 
1.85± 
0.16 
1.87± 
0.18 
1.70± 
0.27* 
II 
2.60± 
0.31 
2.26± 
0.34 
2.05± 
0.37 
1.87± 
0.32 
1.62± 
0.31 
1.62± 
0.44 
Pain 
Interference 
Score (0-10) 
 
 
 
I 
7.00± 
0.64 
6.00± 
0.71 
4.20± 
0.39* 
2.73± 
0.21* 
1.80± 
0.37* 
1.30± 
0.30* 
 
II 
6.72± 
0.66 
6.32± 
0.66 
4.37± 
0.88 
4.02± 
0.57 
2.10± 
0.33* 
1.70± 
0.41* 
Pain from 
Limb 
Manipulation 
(0-4) 
 
 
I 
2.80± 
0.37 
2.40± 
0.24 
2.30± 
0.37 
2.00± 
0.16 
1.80± 
0.20 
0.40± 
0.30* 
II 
3.00± 
0.32 
2.30± 
0.62 
2.50± 
0.16 
2.10± 
0.10 
2.00± 
0.00 
0.60± 
0.29* 
Pain After 
Physical 
Exertion 
(0-4) 
 
 
I 
1.80± 
0.37 
0.80± 
0.58 
0.70± 
0.30 
0.20± 
0.20* 
0.60± 
0.24 
0.20± 
0.20* 
II 
2.40± 
0.40 
1.80± 
0.49 
1.40± 
0.24 
1.20± 
0.37 
0.80± 
0.20 
0.50± 
0.50* 
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Table 2.3. Effects of curcumin on joint flexibility measured by goniometer in osteoarthritic dogs  
 
*Significantly different compared to Day 0 (P < 0.05) 
 
Parameters Group Day 0 Day 30 Day 60 Day 90 Day 120 Day 150 
Right Shoulder 
 
 
 
 
 
I 
56.20± 
9.08 
93.80± 
7.21* 
80.00± 
5.00 
91.20± 
1.88* 
86.00± 
2.53* 
96.40± 
2.50* 
II 
53.20± 
5.90 
80.20± 
7.66* 
82.60± 
2.71* 
86.20± 
4.64* 
89.20± 
3.71* 
93.00± 
4.83* 
Right Elbow 
 
 
 
 
 
I 
79.00± 
14.4 
99.40± 
4.43 
96.20± 
3.53 
98.80± 
2.76 
96.20± 
3.69 
103.40± 
2.31 
II 
77.00± 
11.19 
97.00± 
3.33 
94.00± 
1.87 
94.60± 
2.48 
93.60± 
2.73 
95.80± 
1.15 
Right Stifle 
 
 
 
 
 
I 
59.20± 
11.49 
80.80± 
3.53 
81.60± 
4.23 
85.40± 
5.35 
73.40± 
1.88 
92.40± 
4.50 
II 
50.20± 
9.49 
86.80± 
7.29* 
84.60± 
4.27* 
80.60± 
3.92* 
92.20± 
2.51* 
92.20± 
2.08* 
Left Shoulder 
 
 
 
 
 
I 
60.00± 
6.89 
86.80± 
2.13* 
78.80± 
2.92* 
89.60± 
3.67* 
83.40± 
3.05* 
92.40± 
3.58* 
II 
42.60± 
5.07 
88.20± 
5.90* 
73.20± 
8.56* 
82.40± 
8.20* 
88.80± 
4.80* 
91.60± 
2.46* 
Left Elbow 
 
 
 
 
 
I 
85.8± 
6.81 
95.60± 
3.31 
93.60± 
2.40 
97.00± 
3.00 
94.60± 
4.31 
95.20± 
5.47 
II 
75.00± 
10.72 
92.60± 
6.51 
94.00± 
1.51 
96.00± 
3.67 
89.60± 
0.40 
93.80± 
3.80 
Left Stifle 
 
 
 
 
 
I 
67.60± 
8.15 
87.40± 
5.53 
81.00± 
4.55 
87.00± 
5.26 
84.00± 
4.30 
97.80± 
3.00* 
II 
62.20± 
6.44 
95.60± 
6.99* 
81.60± 
2.04 
83.20± 
5.51 
84.80± 
2.92* 
92.60± 
3.91* 
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Table 2.4. Effects of curcumin on serum biomarkers of liver, kidney, and heart functions in 
osteoarthritic dogs *Significantly different compared to Day 0 (P < 0.05) 
 
Parameters Group Day 0 Day 30 Day 60 Day 90 Day 120 Day 150 
Total Bilirubin 
(mg/dl) 
 
Normal range: 
0.1-0.6 mg/dl 
 
I 
0.16± 
0.02 
0.24± 
0.07 
0.22± 
0.04 
0.16± 
0.02 
0.16± 
0.02 
0.22± 
0.02 
II 
0.22± 
0.05 
0.20± 
0.03 
0.18± 
0.02 
0.14± 
0.02 
0.14± 
0.02 
0.18± 
0.02 
ALT 
(IU/L) 
 
Normal range: 
10-120 IU/L 
 
I 
90.40± 
30.10 
71.00± 
22.78 
90.60± 
31.45 
81.00± 
30.03 
82.80± 
30.96 
72.00± 
29.80 
II 
72.60± 
22.70 
89.80± 
47.70 
46.00± 
13.09 
43.40± 
10.89 
38.20± 
11.29 
40.20± 
10.28 
AST 
(IU/L) 
 
Normal range: 
15-65 IU/L 
 
I 
25.40± 
1.60 
26.20± 
2.29 
27.00± 
2.12 
23.80± 
2.22 
21.60± 
1.24 
25.20± 
2.88 
II 
27.20± 
0.92 
26.20± 
2.58 
21.40± 
1.57 
21.60± 
2.04 
19.60± 
2.25 
24.40± 
1.50 
BUN 
(mg/dl) 
 
Normal range: 
7-26 mg/dl 
 
I 
17.96± 
8.33 
11.60± 
1.17 
12.20± 
1.07 
13.80± 
1.24 
14.20± 
1.31 
15.00± 
3.56 
II 
15.00± 
2.39 
13.00± 
1.48 
16.60± 
1.43 
11.60± 
1.86 
14.00± 
1.30 
14.40± 
1.43 
Creatinine 
(mg/dl) 
 
Normal range: 
0.0-1.35 mg/dl 
 
I 
0.79± 
0.08 
0.86± 
0.09 
0.83± 
0.10 
0.89± 
0.09 
0.93± 
0.11 
0.96± 
0.12 
II 
0.86± 
0.11 
0.88± 
0.10 
0.86± 
0.11 
0.93± 
0.14 
0.92± 
0.12 
0.95± 
0.12 
CK 
(IU/L) 
 
Normal range: 
60-450 IU/L 
 
I 
109.40± 
22.13 
82.20± 
9.87 
101.40± 
22.02 
75.00± 
3.48 
 
82.80± 
13.37 
89.00± 
17.50 
II 
134.40± 
35.11 
106.20± 
30.0 
88.40± 
16.79 
66.40± 
6.50 
69.00± 
10.37 
88.20± 
13.76 
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Table 2.5. Effects of curcumin on complete blood count in osteoarthritic dogs 
 
*Significantly different compared to Day 0 (P < 0.05) 
 
Parameters Group Day 0 Day 30 Day 60 Day 90 Day 120 Day 150 
White Blood 
Cells 
(/µL) 
 
Normal range:  
6-17x10^3/µL 
 
I 
9.48± 
1.11 
10.30± 
1.31 
10.47± 
1.64 
9.26± 
1.28 
9.91± 
1.45 
9.60± 
1.22 
II 
8.63± 
0.63 
8.46± 
0.49 
8.89± 
0.32 
8.26± 
0.87 
8.88± 
1.36 
8.64± 
0.84 
Red Blood 
Cells 
(/µL) 
 
Normal range: 
5.5-8.5x10^6/ 
µL 
 
I 
6.56± 
0.28 
6.97± 
0.34 
6.57± 
0.23 
6.78± 
0.29 
6.3± 
0.25 
6.41± 
0.21 
II 
8.63± 
0.63 
7.10± 
0.42 
6.78± 
0.29* 
7.10± 
0.36 
6.70± 
0.34* 
6.85± 
0.32* 
Hemoglobin 
(g/dL) 
 
Normal range: 
12-18 g/dL 
 
I 
15.98± 
0.95 
17.02± 
0.35 
16.22± 
0.87 
16.72± 
1.03 
15.64± 
0.86 
15.86± 
0.76 
II 
16.34± 
1.31 
16.48± 
1.28 
15.98± 
0.89 
16.86± 
1.21 
16.16± 
1.11 
16.42± 
0.81 
Hematocrit 
(%) 
 
Normal range: 
37-55% 
 
I 
48.86± 
2.18 
51.38± 
2.99 
49.12± 
1.87 
50.34± 
2.43 
45.30± 
1.91 
47.54± 
2.22 
II 
48.62± 
4.21 
50.36± 
3.39 
48.78± 
2.42 
50.94± 
3.21 
46.56± 
2.79 
49.62± 
2.20 
MCV 
(fL) 
 
Normal range: 
60-77 fL 
 
I 
74.48± 
0.68 
73.58± 
0.79 
74.68± 
0.67 
74.12±  
0.59 
71.9± 
0.53 
74.02± 
1.07 
II 
69.18± 
2.19 
70.34± 
1.65 
71.92± 
1.90 
71.66± 
2.03 
69.5± 
1.44 
72.5± 
1.38 
MCH 
(pg) 
 
Normal range: 
19.5-24.5 pg 
 
 
I 
24.28± 
0.42 
24.38± 
0.42 
24.60± 
0.46 
24.56± 
0.45 
24.78± 
0.38 
24.72± 
0.45 
II 
23.32± 
0.62 
22.98± 
0.68 
23.54± 
0.71 
23.70± 
0.76 
24.06± 
0.64 
23.96± 
0.46 
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Table 2.5. (Continued) 
 
MCHC 
(g/dL) 
 
Normal range: 
32-36 g/dL 
I 
32.62± 
0.56 
33.12± 
0.43 
32.92± 
0.55 
33.12± 
0.56 
34.46± 
0.51 
33.36± 
0.46 
II 
33.74± 
0.66 
32.64± 
0.37 
32.72± 
0.25 
33.06± 
0.37 
34.60± 
0.37 
 
33.04± 
0.18 
 
Number of 
Neutrophils 
(/µL) 
 
Normal range: 
3-11.5x10^3/ 
µL 
 
I 
6.50± 
0.77 
6.99± 
1.03 
7.30± 
1.06 
6.18± 
0.77 
6.29± 
0.57 
6.33± 
0.74 
II 
65.44± 
2.24 
65.20± 
3.98 
66.68± 
4.24 
63.34± 
4.01 
63.44± 
3.25 
64.30± 
3.45 
Percentage of 
Neutrophils 
(%) 
 
Normal range: 
60-77% 
 
I 
68.72± 
2.13 
67.40± 
2.48 
70.28± 
1.12 
67.38± 
2.98 
65.54± 
3.95 
66.54± 
3.54 
II 
65.44± 
2.24 
65.20± 
3.98 
66.68± 
4.24 
63.34± 
4.01 
63.44± 
3.25 
64.30± 
3.45 
Number of 
Lymphocytes 
(/µL) 
 
Normal range: 
1-4.8x10^3/ µL 
 
I 
1.87± 
0.22 
2.10± 
0.24 
1.97± 
0.35 
1.91± 
0.37 
2.16± 
0.49 
2.08± 
0.39 
II 
2.14± 
0.25 
2.02± 
0.27 
2.12± 
0.25 
2.16± 
0.36 
2.16± 
0.18 
2.16± 
0.27 
Percentage of 
Lymphocytes 
(%) 
 
Normal range: 
12-30% 
 
I 
20.12± 
1.76 
21.18± 
2.18 
19.40± 
2.35 
21.08± 
2.93 
21.42± 
2.13 
21.90± 
2.67 
II 
24.68± 
1.57 
23.76± 
2.41 
24.82± 
3.06 
26.36± 
3.32 
25.44± 
2.23 
25.42± 
3.10 
Number of 
Monocytes 
(/µL) 
 
Normal range: 
0.1-1.4x10^3/ 
µL 
 
I 
0.37± 
0.06 
 
0.40± 
0.05 
 
0.37± 
0.06 
 
0.38± 
0.08 
 
0.45± 
0.09 
 
0.36± 
0.06 
II 
0.38± 
0.05 
0.40± 
0.07 
0.37± 
0.06 
0.33± 
0.07 
0.40± 
0.08 
0.34± 
0.05 
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Table 2.5. (Continued) 
 
Percentage of 
Monocytes 
(%) 
 
Normal range: 
3-10% 
 
I 
 3.90± 
0.54 
 3.92± 
0.39 
 3.60± 
0.52 
 4.02± 
0.62 
 4.50± 
0.58 
 3.78± 
0.65 
II 
 4.38± 
0.45 
 4.74± 
0.88 
 4.16± 
0.66 
 3.88± 
0.55 
 4.40± 
0.49 
  3.92± 
0.44 
Number of 
Eosinophils 
(/µL) 
 
Normal range: 
0.1-1.2x10^3/ 
µL 
I 
  0.72± 
0.26 
  0.79± 
0.20 
  0.82± 
0.39 
  0.78± 
0.32 
  0.98± 
0.47 
  0.81± 
0.29 
II 
 
  0.47± 
0.09 
  0.52± 
0.14 
  0.37± 
0.10 
 0.52± 
     0.08 
 0.54± 
0.11 
  0.53± 
0.10 
Percentage of 
Eosinophils 
(%) 
 
Normal range: 
2-10% 
 
I 
  7.12± 
1.83 
  7.46± 
1.42 
  6.66± 
2.86 
 7.44± 
2.38 
  8.46± 
3.09 
 7.70± 
1.86 
II 
  5.32± 
0.78 
  6.22± 
1.55 
  4.28± 
1.25 
  6.36± 
1.20 
  6.62± 
1.74 
  6.28± 
1.21 
Number of 
Basophils 
(/µL) 
 
Normal range: 
0-0.05x10^3/ 
µL 
 
I 
   0.01 ± 
0.00 
  0.00± 
0.00 
  0.00± 
0.00 
  0.01± 
0.00 
  0.01± 
0.00 
  0.00± 
0.00 
II 
  0.01± 
0.00 
  0.01± 
0.00 
  0.01± 
0.00 
  0.01± 
0.01 
  0.01± 
0.00 
  0.01± 
0.00 
Percentage of 
Basophils 
(%) 
 
Normal range: 
0-0.5% 
 
I 
  0.12± 
0.02 
  0.04± 
0.02 
  0.06± 
0.02 
  0.08± 
0.02 
  0.08± 
0.04 
  0.08± 
0.02 
II 
 0.18± 
0.03 
 0.08± 
0.04 
 0.06± 
0.02 
 0.06± 
0.05 
 0.10± 
0.03 
  0.08± 
0.03 
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CHAPTER 3 
THERAPEUTIC AND SAFETY EVALUATION OF CURCUMIN AND LIPOSOMAL-
CURCUMIN IN MODERATELY ARTHRITIC DOGS: PHASE 2 
ABSTRACT: 
 The objective of this investigation was to evaluate the efficacy and safety of two different 
dosages of 95% curcumin (100 mg and 500 mg, once daily) in moderately arthritic dogs. Ten 
client-owned dogs, in a randomized, double-blinded study, received either 500 mg of 95% 
curcumin once a day (SID) or 100 mg of 95% curcumin once a day, for a period of five months. 
Dogs were evaluated each month for physical condition (body weight, body temperature, heart 
rate, and respiratory rate), pain associated with arthritis (overall pain, pain during limb 
manipulation, and pain after two minutes of physical exertion), and range of motion was 
measured using a goniometer on the shoulder, elbow, and stifle joints. Serum samples collected 
from these dogs were examined each month for biomarkers of the liver (total bilirubin, ALT, and 
AST), kidney (BUN and creatinine), heart and muscle (creatine kinase) functions. Whole blood 
samples were also analyzed to detect inflammation biomarkers using an Autozero Westergren 
erythrocyte sedimentation rate test. The findings of this study revealed that dogs receiving 95% 
curcumin, 500 mg, SID (Group-III) and 95% curcumin, 100 mg, SID (Group-IV) had a 
significant (P < 0.0001) reduction in pain of overall pain, pain of limb manipulation, and pain 
after physical exertion by day 150. Group-III had a significant reduction in overall pain by day 
60 and Group-IV showed significant reduction in overall pain by day 90. Both groups had a 
significant reduction in pain during limb manipulation and after physical exertion on day 90. 
Dogs in either group had no significant changes (P > 0.05) in physical parameters or serum 
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markers, suggesting that both treatments, 500 mg and 100 mg of 95% curcumin, were well 
tolerated by moderately arthritic dogs. It was concluded that both, 500 mg and 100 mg of 95% 
curcumin, significantly (P < 0.05) reduced pain in osteoarthritic dogs and markedly improved 
their daily life activity without any side effects.    
INTRODUCTION 
Osteoarthritis is the most common type of arthritis in dogs and is the most common 
source of chronic pain in older dogs (Gupta et al., 2009; Gupta et al., 2011). Osteoarthritis is a 
chronic inflammatory joint disease, which causes pain/soreness, stiffness, swelling, and 
lameness, due to the diminished cushion and changes in the synovial fluid (Vaughn-Scott et al., 
1997; Pasquini et al., 2007). Osteoarthritis affects the entire synovial joint, including the 
cartilage, synovial fluid, and bone. Mechanical stress is thought to induce changes in 
biochemical factors within affected joints, leading to articular cartilage degradation (Renberg, 
2005). All of these changes in the joints and bones can cause pain, swelling, and enlargement of 
the joints, which can affect the quality of life. Arthritis mainly affects large breed dogs, i.e. 
German Shepherds, Labradors Retrievers, Siberian Huskies, and Rottweilers, more than small 
breed dogs. However, presently, one in four dogs are being diagnosed with osteoarthritis in the 
United States. Dogs that are diagnosed with arthritis tend to display signs of lethargy, have 
difficulty moving from a sitting or lying position, cracking joints, stiffness, muscle wastage, and 
visible pain (Gupta et al., 2009; Gupta et al., 2011). Diagnosing osteoarthritis in dogs begins with 
owners observing the pain and stiffness while the animal is running, walking, jumping, or rising 
from a lying or sitting position. Properly diagnosing patients with osteoarthritis will help 
establish a future treatment plan to help ease the pain.  
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Pharmacological management of osteoarthritis includes steroidal or non-steroidal anti-
inflammatory (NSAID) agents. However, these drugs just control pain and inflammation and do 
not address the underlying issue. NSAIDs work against prostaglandins, which are a family of 
chemicals that are produced by cells and promote inflammation. NSAIDs have a high risk of 
toxicity and multiple adverse side effects, due to this; there is a push for alternative treatments in 
the form of food supplements such as nutraceuticals. 
A nutraceutical is defined as a food, typically plant based, which provides medicinal or 
health benefits, including the prevention and treatment of diseases (Rajat et al., 2012). Currently, 
there are over 470 nutraceuticals with documented health benefits (Rajet et al., 2012).  
Curcumin, the active ingredient of turmeric, is isolated from the plant Curcuma longa. Curcumin 
is a member of the curcuminoid family and is closely related to ginger. Curcumin, 
diarylheptanoid, has been extensively studied for over 30 years, and past studies have shown that 
curcumin plays a vital role in preventing and treating a wide range of pro-inflammatory chronic 
diseases such as cardiovascular, pulmonary, autoimmune, and neurodegenerative diseases 
(Prasad et al., 2014). In addition, curcumin is also known for other medicinal benefits, including 
anti-inflammatory, anti-oxidant, wound healing, and antimicrobial properties (Prasad et al., 
2014). Three main curcuminoids that are seen in commercial supplements are curcumin 
(curcumin I), demethoxycurcumin (curcumin II), and bis-demethoxycurcumin (curcumin III) 
(Figure 3.1). These curcuminoids are said to work synergistically and have a greater effect 
compared to if used alone (Wynn and Fougere, 2008). 
According to past studies, curcumin can possibly affect the progression of arthritis by 
preventing degradation and enhancing the repair of joint cartilage (Sanghi et al., 2008). 
Curcumin can also inhibit pro-inflammatory transcription factors, nuclear factor-kappaβ, as well 
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as inhibit inflammatory cytokines, including TNF and cyclooxygenases-2 (Prasad et al., 2014). 
Overall, curcumin seems to be an ideal alternative treatment due to significant evidence pointing 
towards it as a potent agent against chronic diseases without being toxic to any metabolic 
pathways (Prasad et al., 2014).  
Despite curcumin’s medicinal benefits, the downfalls of curcumin are noted to be its poor 
aqueous solubility, low bioavailability, and its staining properties (Anard et al., 2009). 
Curcumin’s low bioavailability is due to its poor absorption, bio-distribution, and quick rate of 
metabolism. Multiple studies have tried increasing curcumin’s bioavailability, longer circulation, 
and resistance to metabolic processes by changing the preparation of the formula to include 
nanoparticles, micelles, liposomes, and phospholipids (Li et al., 2007; Anard et al., 2009; Li et 
al., 2011; Prasad et al., 2014). Due to curcumin being a nutraceutical and only having 
recommended dosages available, it is vital to identify the therapeutic dosage of curcumin anti-
inflammatory properties in dogs. In the present investigation, 95% curcumin was evaluated for 
its therapeutic and safety evaluation in osteoarthritic dogs. 
MATERIALS AND METHODS 
Animals 
 Ten client-owned moderately arthritic dogs, weighing between 40-65 pounds, 8 ± 3 
years, were used in this study. These dogs, based on signs of joint stiffness, lameness, and degree 
of range of motion, had pain at the level of moderate arthritis. My inclusion criteria of dogs in 
this study excluded those having any concurrent diseases (liver, kidney, or heart disease, 
neoplasia, cancer or any other major disease). All dogs were tested and were heartworm negative 
for the entire duration of the study. Institutional Animal Care and Use Committee (IACUC) 
approval and owners’ consent were obtained prior to the initiation of this study. 
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Experimental Design 
 In a randomized double-blind study, ten client-owned dogs, divided into two groups (n = 
5), received 95% curcumin, 500 mg, once a day (Group-III) or 95% curcumin, 100 mg, once a 
day (Group IV). The study was carried out for a period of five months at Murray State 
University. None of the dogs received any treatment or supplements four weeks prior to the 
study or during the study period.   
Pain Measurement 
 At pre-determined intervals (i.e. 30 days), each dog was evaluated for overall pain, pain 
upon limb manipulation, and pain after physical exertion, for a period of five months. Overall 
pain, on a scale of 0-10, was graded as: 0, no pain: 2.5, mild pain: 5, moderate pain: 7.5, severe 
pain: 10, severe and constant pain. Pain after manipulation, on a scale of 0-4, was evaluated as: 
0, no pain: 1, mild pain: 2, moderate pain: 3, severe pain: 4, severe and constant pain. Pain after 
physical exertion, on a scale of 0-4, was evaluated as: no pain: 0, no pain: 1, mild pain: 2, 
moderate pain: 3, severe pain: 4, severe and constant pain. Range of motion was evaluated with a 
goniometer and the degree of motion during flexion was noted. The physical examination of 
each limb started with the forelimbs and ended with the hind limbs. The evaluation focused on 
manipulation of the limbs in a forward, backward, and circular motion. Three main joints in each 
dog were evaluated, including the shoulder joint, elbow joint, and stifle joint, which are the top 
three joints that are affected by osteoarthritis in dogs. Popping and cracking of the joints as well 
as vocal pain were noted for each canine during examination. Detailed criteria of the 
measurement of pain are provided in our earlier publications (Deparle et al., 2005; Peal et al., 
2007; D'Altilio et al., 2007; Gupta et al., 2009; Gupta et al., 2011; Fleck et al., 2013; Lawley et 
al., 2013). The present investigation was carried out on moderately arthritic dogs. A moderately 
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arthritic dog exhibits overall pain of about a 5 on a scale of 0-10, pain upon limb manipulation 
about a 2 on a scale of 0-4, and pain after physical exertion about a 2 on a scale of 0-4. 
Physical Examination 
 On a monthly basis, dogs were given a full physical examination for body weight, body 
temperature, heart rate, and respiratory rate (Table 3.1).  
Serum Biomarkers Assays 
 Blood samples were collected from the cephalic vein using a 3 mL syringe with a 22-
gauge, 1-inch needle and were stored in a marble top tube (serum separator tubes) and lavender 
top tube (EDTA tubes). Samples in the marble top tubes were then spun to collect serum and 
transferred to a red top tube for evaluation. Serum samples were collected each month and 
analyzed for liver (total bilirubin, ALT, and AST), kidney (BUN and creatinine), heart and 
muscle (CK) functions, using a Beckman AU 480 serum analyzer. The lavender top tubes were 
analyzed for a complete blood count, including a five-part differential (neutrophils, lymphocytes, 
monocytes, eosinophils, and basophils). Whole blood, stored in lavender top tubes, was collected 
each month to analyze the effects of curcumin on red blood cells and white blood cells (Table 
3.4). Whole blood was also analyzed for the presences of inflammation biomarkers by 
performing an erythrocyte sedimentation rate test (Table 3.5) using the Autozero Westergren 
erythrocyte sedimentation rate (ESR) system (Globe Scientific Inc.).  
Statistical Analysis 
 The data presented are means ± SEM (n = 5). Statistical significance of difference 
between each month compared to baseline (day 0) was determined by analysis of variance 
(ANOVA) coupled with Tukey-Kramer post-hoc test (P < 0.05) using the Statistical Analysis 
and Graphics Software for Windows (NCSS9). 
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RESULTS 
 On a monthly basis, each dog was examined for pain level (overall pain, pain during limb 
manipulation, and pain after physical exertion), shown in Figures 3.2-3.4. Overall pain was 
assessed by the dog’s gait, joint range of motion, ability to sit or lie down, and ability to rise 
from a seated or lying position. Group-III dogs, receiving 500 mg of 95% curcumin, had a 
significant (P < 0.0001) reduction in overall pain by day 60 (4.40 ± 0.29) compared to day 0 
(5.90 ± 0.24). The maximum reduction in overall pain was noted on day 150 (2.90 ± 0.29). 
Group-IV dogs, receiving 100 mg of 95% curcumin, had a significant (P = 0.002) reduction in 
overall pain on day 90 (3.80 ± 0.25) compared to day 0 (6.30 ± 0.43). The maximum reduction in 
overall pain was noted on day 150 (3.00 ± 0.71). 
 Pain during limb manipulation was measured in each limb of the dog for flexibility, joint 
integrity, and vocalization. The pain level during limb manipulation for Group-III was 
significantly (P = 0.02) reduced by day 90 (1.30 ± 0.12), compared to day 0 (2.60 ± 0.18). The 
pain level during limb manipulation for Group-IV was significantly (P = 0.04) reduced by day 60 
(1.95 ± 0.16) compared to day 0 (3.00 ± 0.00). The canines were also evaluated for pain after 
two minutes of jogging. After jogging, pain level was assessed based on the dog’s body position, 
signs of pain or limping, flexibility, and vocalization. Group-III and Group-IV had a notably 
significant reduction in pain after physical exertion on day 60 (1.60 ± 0.10) and (1.80 ± 0.12), 
respectively.  
 Data of physical parameters (body weight, body temperature, heart rate, and respiratory 
rate) are shown in Table 3.1, and were within normal range. Dogs in both groups did not have 
any significant changes in any of the physical parameters. Dogs in both groups also did not have 
any significant changes in the serum biomarkers during the duration of the study (Table 3.4). 
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Although the erythrocyte sedimentation rate test showed a decreasing trend for both groups, it 
was not significantly different compared to day 0 (Table 3.5).  
DISCUSSION 
 In the present paper, we report that 95% curcumin at a dose of 500 mg or 100 mg, SID, is 
effective in reducing arthritic pain and enhancing the daily activity and quality of the dog’s life 
without exerting any side effects. Curcumin administration can aid in alleviating pain in all three 
categories (overall pain, pain during limb manipulation, and pain after physical exertion) with a 
maximum reduction noted on day 150. Curcumin, the active ingredient in turmeric, is widely 
known for its anti-oxidant and anti-inflammatory properties, which makes it a promising 
nutraceutical for arthritic dogs. In addition to reducing arthritic pain, curcumin has been used as 
a preventative treatment for bowel disease, pancreatitis, skin conditions, pulmonary and 
gastrointestinal issues, wound healing, sprains, liver disorders, and cancers. While testing 
therapeutic dosages, further research needs to be conducted examining the same dosages with a 
controlled diet and exercise plan. 
 In conclusion, curcumin offers significant anti-arthritic properties, including reduction of 
overall pain and inflammation, increasing range of motion, especially in the stifle joint, and help 
reduce pain during limb manipulation and after physical exertion. All dogs responded well to 
curcumin administration without experiencing any adverse side effects; therefore, giving the 
supplement a competitive edge over many other anti-arthritic pharmaceuticals.  
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Figure 3.1. Chemical structures of curcumin I, II, and III and derivatives 
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Figure 3.2. Effects of 500 mg of 95% curcumin (Group-III) or 100 mg of 95% curcumin 
(Group-IV) on overall pain in moderately arthritic dogs.  
Overall pain was graded on a scale of 0-10 (0, no pain: 2.5, mild pain: 5, moderate pain: 7.5, 
severe pain: 10, severe and constant pain).  
*Significantly different compared to Day 0 (P < 0.05) 
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Figure 3.3. Effects of 500 mg of 95% curcumin (Group-III) or 100 mg of 95% curcumin 
(Group-IV) on pain during limb manipulation in moderately arthritic dogs.  
Pain from limb manipulation was graded on a scale of 0-4 (0, no pain: 1, mild pain: 2, moderate 
pain: 3, severe pain: 4, severe and constant pain). 
*Significantly different compared to Day 0 (P < 0.05) 
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Figure 3.4.Effects of 500 mg of 95% curcumin (Group-III) or 100 mg of 95% curcumin (Group-
IV) on pain after physical exertion in moderately arthritic dogs. 
Pain from limb manipulation was graded on a scale of 0-4 (0, no pain: 1, mild pain: 2, moderate 
pain: 3, severe pain: 4, severe and constant pain). 
*Significantly different compared to Day 0 (P < 0.05) 
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Table 3.1. Effects of curcumin on physical parameters in osteoarthritic dogs 
 
*Significantly different compared to Day 0 (P < 0.05) 
Parameters Group Day 0 Day 30 Day 60 Day 90 Day 120 Day 150 
Body Weight 
(lbs) 
 
 
 
 
III 
58.04± 
5.14 
58.04± 
5.14 
57.28± 
5.34 
57.20± 
4.36 
57.00± 
5.15 
55.92± 
5.15 
IV 
59.56± 
6.71 
58.40± 
6.62 
59.60± 
6.53 
58.48± 
5.81 
57.84± 
5.75 
59.20± 
5.96 
Temperature 
(°F) 
 
Normal range: 
101-102.5°F 
 
III 
101.46± 
0.53 
100.8± 
0.28 
100.20±
0.22 
101.10± 
0.15 
100.08± 
1.03 
100.92± 
0.18 
IV 
101.66± 
0.25 
101.62± 
0.19 
100.26±
0.66 
100.00± 
0.12 
99.78± 
0.34 
100.18± 
0.20 
Heart Rate 
(bpm) 
 
Normal range: 
70-160 bpm 
 
III 
109.20± 
14.72 
198.80± 
7.84 
96.40± 
14.78 
99.60± 
9.21 
106.80± 
5.04 
93.60± 
12.05 
IV 
123.20± 
11.67 
135.50± 
12.78 
120.00±
6.12 
110.40± 
11.49 
108.40± 
12.10 
102.40± 
14.45 
Respiratory 
Rate 
(bpm) 
 
Normal range: 
10-35 bpm 
 
III 
19.66± 
2.49 
21.60± 
2.40 
22.00± 
2.00 
20.60± 
1.66 
21.60± 
2.48 
23.60± 
2.40 
IV 
23.80± 
2.90 
24.00± 
2.45 
22.80± 
1.20 
23.60± 
1.83 
24.20± 
3.35 
27.20± 
2.73 
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Table 3.2. Effects of curcumin on arthritis associated pain level in osteoarthritic dogs 
 
*Significantly different compared to Day 0 (P < 0.05) 
Parameters Group Day 0 Day 30 Day 60 Day 90 Day 120 Day 150 
Overall Pain 
Score (0-10) 
 
 
 
 
 
III 
5.90± 
0.24 
5.30± 
0.20 
4.40± 
0.29* 
3.40± 
0.29* 
3.30± 
0.30* 
2.90± 
0.29* 
IV 
6.30± 
0.43 
5.70± 
0.46 
4.80± 
0.37 
3.80± 
0.25* 
3.20± 
0.49* 
3.00± 
0.71* 
Pain Severity 
Score (0-10) 
 
 
 
 
 
III 
4.80± 
0.49 
5.00± 
0.42 
4.90± 
0.85 
2.85± 
0.34 
3.60± 
0.92 
2.90± 
0.29 
IV 
5.30± 
0.66 
4.70± 
0.71 
4.90± 
0.90 
3.77± 
0.66 
3.90± 
1.31 
3.40± 
0.96 
Pain 
Interference 
Score (0-10) 
 
 
 
 
III 
5.66± 
0.36 
4.73± 
0.58 
4.29± 
0.49 
2.82± 
0.22* 
3.25± 
0.95 
3.06± 
0.60* 
IV 
6.36± 
0.62 
5.58± 
0.71 
4.69± 
0.69 
3.96± 
0.76 
3.87± 
1.21 
3.70± 
1.00 
Pain from 
Limb 
Manipulation 
(0-4) 
 
 
 
 
III 
2.60± 
0.18 
2.20± 
0.20 
1.80± 
0.20 
1.30± 
0.12* 
1.40± 
0.18* 
0.70± 
0.20* 
IV 
3.00± 
  0.00 
2.40± 
0.18 
1.95± 
0.16* 
1.70± 
0.20* 
1.60± 
0.18* 
1.10± 
0.18* 
Pain After 
Physical 
Exertion 
(0-4) 
 
 
 
 
III 
2.10± 
  0.10 
1.80± 
0.12 
1.60± 
0.10* 
1.35± 
0.10* 
1.25± 
0.11* 
0.60± 
0.10* 
IV 
2.70± 
  0.20 
2.10± 
0.10 
1.80± 
0.12* 
1.45± 
0.16* 
1.40± 
1.87* 
1.10± 
0.18* 
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Table 3.3. Effects of curcumin on joint flexibility measured by goniometer in osteoarthritic dogs  
 
*Significantly different compared to Day 0 (P < 0.05) 
 
Parameters Group Day 0 Day 30 Day 60 Day 90 Day 120 Day 150 
Right Shoulder 
 
 
 
 
 
III 
69.00± 
4.84 
55.00± 
4.30 
57.00± 
12.51 
70.00± 
1.58 
74.00± 
1.58 
82.00± 
3.74 
IV 
66.00± 
10.77 
64.00± 
4.30 
73.00± 
3.39 
69.00± 
3.31 
76.80± 
4.33 
85.00± 
3.53 
Right Elbow 
 
 
 
 
 
III 
94.00± 
4.30 
86.00± 
1.58 
97.00± 
7.17 
99.00± 
8.86 
100.00± 
6.51 
109.00± 
4.58 
IV 
85.00± 
6.70 
79.00± 
5.78 
93.00± 
3.74 
91.00± 
7.81 
96.00± 
4.00 
104.00± 
6.96 
Right Stifle 
 
 
 
 
 
III 
74.00± 
4.00 
82.00± 
5.15 
94.00± 
1.87 
89.00± 
7.64 
96.00± 
5.56* 
110.00± 
1.58* 
IV 
63.00± 
5.14 
69.00± 
4.30 
84.00± 
5.09 
79.00± 
6.20 
78.00± 
5.14 
98.00± 
3.39* 
Left Shoulder 
 
 
 
 
 
III 
81.00± 
4.00 
70.00± 
2.74 
76.00± 
4.30 
75.00± 
2.23 
75.00± 
3.16 
91.00± 
1.87 
IV 
60.00± 
5.70 
68.00± 
2.00 
75.00± 
5.70 
76.00± 
1.86 
72.00± 
3.74 
82.00± 
3.39 
Left Elbow 
 
 
 
 
 
III 
96.00± 
1.00 
95.00± 
2.74 
96.00± 
8.12 
102.00± 
3.39 
96.00± 
2.45 
100.00± 
7.41 
IV 
87.00± 
5.38 
87.00± 
3.39 
88.00± 
6.81 
96.00± 
4.58 
98.00± 
3.74 
103.00± 
6.44 
Left Stifle 
 
 
 
 
 
III 
57.00± 
6.63 
66.00± 
5.09 
78.00± 
5.83 
93.00± 
7.00 
94.00± 
3.31 
103.00± 
6.63 
IV 
68.00± 
5.83 
61.00± 
8.28 
72.00± 
2.00 
79.00± 
4.30* 
82.00± 
5.83* 
97.00± 
1.22* 
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Table 3.4. Effects of curcumin on serum biomarkers of liver, kidney, heart, and muscle functions  
 
in osteoarthritic dogs *significantly different compared to Day 0 (P < 0.05) 
 
Parameters Group Day 0 Day 30 Day 60 Day 90 Day 120 Day 150 
Total Bilirubin 
(mg/dl) 
 
Normal range: 
0.1-0.6 mg/dl 
 
III 
0.30± 
0.05 
0.18± 
0.02 
0.24± 
0.05 
0.18± 
0.03 
0.20± 
0.03 
0.10± 
0.00 
IV 
0.20± 
0.05 
0.32± 
0.10 
0.26± 
0.04 
0.18± 
0.04 
0.16± 
0.02 
0.14± 
0.02 
ALT 
(IU/L) 
 
Normal range: 
10-120 IU/L 
 
III 
55.80± 
24.44 
67.20± 
25.18 
63.80± 
24.58 
70.40± 
24.50 
56.00± 
20.53 
55.60± 
22.32 
IV 
45.00± 
5.30 
38.60± 
2.91 
41.40± 
2.01 
46.20± 
5.80 
45.00± 
2.05 
49.20± 
5.75 
AST 
(IU/L) 
 
Normal range: 
15-65 IU/L 
 
III 
29.40± 
2.62 
25.40± 
1.91 
25.20± 
2.22 
27.80± 
3.31 
26.2± 
1.83 
25.60± 
2.69 
IV 
25.40± 
2.33 
29.00± 
4.83 
25.20± 
0.80 
25.60± 
1.63 
26.80± 
1.98 
25.80± 
2.31 
BUN 
(mg/dl) 
 
Normal range: 
7-26 mg/dl 
 
III 
17.80± 
1.71 
17.60± 
1.21 
17.00± 
1.58 
16.60± 
1.60 
16.60± 
1.77 
18.8± 
1.39 
IV 
15.00± 
2.07 
15.20± 
2.20 
13.6± 
1.56 
13.60± 
1.43 
12.80± 
1.56 
14.40± 
1.74 
Creatinine 
(mg/dl) 
 
Normal range: 
0.0-1.35 mg/dl 
 
III 
1.09± 
0.11 
0.95± 
0.09 
1.02± 
0.07 
0.95± 
0.08 
0.97± 
0.11 
0.95± 
0.08 
IV 
0.95± 
0.09 
0.90± 
0.10 
0.95± 
0.10 
0.96± 
0.09 
0.87± 
0.08 
0.89± 
0.08 
CK 
(IU/L) 
 
Normal range: 
60-450 IU/L 
 
III 
97.80± 
16.09 
106.00± 
28.37 
88.00± 
19.21 
113.20± 
22.27 
100.60± 
13.12 
94.40± 
14.00 
IV 
127.6± 
45.52 
159.00± 
41.57 
114.00± 
20.17 
111.20± 
21.47 
140.80± 
21.09 
116.80± 
19.54 
 
 
 
 
 
  
75 
Table 3.5. Effects of curcumin on complete blood count in osteoarthritic dogs  
*Significantly different compared to Day 0 (P < 0.05) 
Parameters Group Day 0 Day 30 Day 60 Day 90 Day 120 Day 150 
White Blood 
Cells 
(/µL) 
 
Normal range:  
6-17x10^3/µL 
 
III 
10.46± 
0.91 
9.29± 
1.00 
10.00± 
1.57 
10.08± 
1.06 
8.64± 
0.86 
10.00± 
1.57 
IV 
8.83± 
0.64 
8.88± 
0.85 
8.19± 
0.97 
8.30± 
0.84 
7.46± 
0.69 
8.11± 
1.02 
Red Blood Cells 
(/µL) 
 
Normal range: 
5.5-8.5x10^6/ 
µL 
 
III 
7.37± 
0.35 
7.20± 
0.25 
7.35± 
0.31 
7.29± 
0.24 
7.55± 
0.38 
7.35± 
0.31 
IV 
7.63± 
0.24 
7.42± 
0.34 
7.71± 
0.31 
7.74± 
0.33 
7.67± 
0.24 
7.75± 
0.38 
Hemoglobin 
(g/dL) 
 
Normal range: 
12-18 g/dL 
 
III 
17.56± 
0.64 
17.02± 
0.55 
17.40± 
0.48 
17.26± 
0.48 
17.94± 
0.76 
17.40± 
0.48 
IV 
18.10± 
0.63 
17.50± 
0.84 
18.28± 
0.73 
18.38± 
0.72 
18.14± 
0.24 
18.25± 
0.92 
Hematocrit 
(%) 
 
Normal range: 
37-55% 
 
III 
50.46± 
1.82 
52.58± 
2.05 
51.52± 
1.73 
51.62± 
1.87 
53.98± 
2.44 
51.52± 
1.73 
IV 
53.84± 
1.52 
55.24± 
2.10 
56.36± 
1.13 
57.06± 
1.43 
57.22± 
1.77 
55.70± 
2.19 
MCV 
(fL) 
 
Normal range: 
60-77 fL 
 
III 
68.68± 
1.72 
73.04± 
1.65 
70.26± 
1.76 
70.92± 
1.70 
71.62± 
1.77 
70.26± 
1.76 
IV 
70.74± 
2.06 
74.62± 
1.49 
73.38± 
2.00 
73.94± 
2.39 
74.66± 
1.82 
72.12± 
2.25 
MCH 
(pg) 
 
 
Normal range: 
19.5-24.5 pg 
 
 
III 
23.86± 
0.41 
23.66± 
0.39 
23.72± 
0.46 
23.70± 
0.51 
23.78± 
0.35 
23.72± 
0.46 
IV 
23.72± 
0.31 
23.58± 
0.31 
23.74± 
0.34 
23.78± 
0.55 
23.64± 
0.32 
23.57± 
0.34 
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Table 3.5. (Continued) 
 
MCHC 
(g/dL) 
 
Normal range: 
32-36 g/dL 
 
III 
34.76± 
0.36 
32.38± 
0.29 
33.80± 
0.35 
33.44± 
0.38 
33.26± 
0.46 
33.80± 
0.35 
IV 
33.62± 
0.71 
31.64± 
0.61 
32.40± 
0.74 
32.20± 
0.62 
31.68± 
0.56 
32.77± 
0.69 
Number of 
Neutrophils 
(/µL) 
 
Normal range: 
3-11.5x10^3/ 
µL 
 
III 
6.11± 
0.44 
5.76± 
0.64 
6.00± 
0.93 
6.44± 
0.79 
5.23± 
0.75 
6.00± 
0.93 
IV 
6.01± 
0.41 
6.29± 
0.69 
5.70± 
0.78 
5.58± 
0.68 
5.04± 
0.45 
5.22± 
0.65 
Percentage of 
Neutrophils 
(%) 
 
Normal range: 
60-77% 
 
 
III 
59.30± 
4.11 
 
62.28± 
4.70 
60.02± 
3.70 
63.52± 
3.55 
59.82± 
4.77 
60.02± 
3.70 
IV 
68.34± 
1.70 
70.62± 
2.14 
68.94± 
1.49 
67.02± 
3.04 
67.70± 
1.73 
64.82± 
4.46 
Number of 
Lymphocytes 
(/µL) 
 
Normal range: 
1-4.8x10^3/ µL 
 
III 
3.10± 
0.45 
2.42± 
0.38 
2.81± 
0.47 
2.51± 
0.26 
2.35± 
0.25 
2.81± 
0.47 
IV 
1.79± 
0.13 
1.58± 
0.10 
1.64± 
0.10 
1.65± 
0.07 
1.34± 
0.03 
1.71± 
2.32 
Percentage of 
Lymphocytes 
(%) 
 
Normal range: 
12-30% 
 
III 
29.34± 
2.73 
26.58± 
4.13 
28.62± 
3.03 
25.62± 
2.97 
28.10± 
3.44 
28.62± 
3.03 
IV 
20.64± 
1.99 
18.3± 
1.76 
20.72± 
1.49 
20.30± 
1.45 
18.62± 
1.82 
21.80± 
2.32 
Number of 
Monocytes 
(/µL) 
 
Normal range: 
0.1-1.4x10^3/ 
µL 
 
III 
0.42± 
0.09 
0.43± 
0.12 
0.43± 
0.10 
0.50± 
0.15 
0.37± 
0.85 
0.43± 
0.10 
IV 
0.37± 
0.05 
0.37± 
0.04 
0.40± 
0.07 
0.36± 
0.06 
0.31± 
0.04 
0.36± 
0.07 
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Table 3.5. (Continued) 
 
Percentage of 
Monocytes 
(%) 
 
Normal range: 
3-10% 
 
III 
3.98± 
0.69 
4.44± 
0.70 
4.26± 
0.60 
4.74± 
0.95 
4.16± 
0.59 
4.26± 
0.60 
IV 
4.22± 
0.55 
4.24± 
0.35 
4.88± 
0.64 
4.38± 
0.56 
4.24± 
0.68 
4.32± 
0.53 
Number of 
Eosinophils 
(/µL) 
 
Normal range: 
0.1-1.2x10^3/ 
µL 
 
III 
0.79± 
0.25 
0.66± 
0.27 
0.75± 
0.29 
0.60± 
0.21 
0.67± 
0.18 
0.75± 
0.29 
IV 
0.63± 
0.23 
0.63± 
0.16 
0.43± 
0.64 
0.69± 
0.27 
0.76± 
0.27 
0.81± 
0.46 
Percentage of 
Eosinophils 
(%) 
 
Normal range: 
2-10% 
 
III 
7.24± 
1.86 
6.58± 
2.43 
6.94± 
2.25 
5.94± 
1.75 
7.78± 
1.93 
6.94± 
2.25 
IV 
6.74± 
2.03 
6.76± 
1.41 
5.32± 
0.36 
8.22± 
2.66 
9.36± 
2.45 
9.02± 
3.96 
Number of 
Basophils 
(/µL) 
 
Normal range: 
0-0.05x10^3/ 
µL 
 
III 
0.02± 
0.01 
0.01± 
0.00 
0.01± 
0.00 
0.02± 
0.00 
0.01± 
0.00 
0.01± 
0.00 
IV 
0.01± 
0.00 
0.00± 
0.00 
0.01± 
0.00 
0.00± 
0.00 
0.00± 
0.00 
0.00± 
0.00 
Percentage of 
Basophils 
(%) 
 
Normal range: 
0-0.5% 
 
III 
0.14± 
0.05 
0.12± 
0.04 
0.16± 
0.06 
0.18± 
0.05 
0.14± 
0.50 
0.16± 
0.06 
IV 
0.06± 
0.02 
0.08± 
0.02 
0.14± 
0.02 
0.08± 
0.02 
0.08± 
0.37 
0.02± 
0.02 
Erythrocyte 
Sedimentation 
Rate 
(mm/hr) 
 
Normal range: 
0-5mm/hr 
III 
3.20± 
1.20 
3.60± 
0.51 
3.40± 
0.81 
2.20± 
0.37 
3.60± 
0.51 
2.20± 
0.20 
IV 
2.80± 
0.49 
4.8± 
1.24 
2.40± 
0.60 
2.60± 
0.51 
2.00± 
0.31 
2.30± 
0.43 
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CHAPTER 4 
EFFECTS OF TURMERIC, CURCUMIN, AND LIPSOMAL-CURCUMIN ON BACTERIA 
FOUND IN THE EQUINE HINDGUT- AN IN VITRO STUDY 
ABSTRACT: 
The purpose of this study was to investigate both form and dose of turmeric and its active 
ingredient, curcumin, on reducing opportunistic bacteria found in the equine hindgut. The 
bacterial strains of interest included Streptococcus bovis/equinus complex (SBEC), Escherichia 
coli K-12, Escherichia coli general, Clostridium difficile, and Clostridium perfringens. The first 
in vitro, 24 h batch culture, consisted of the following treatments; 1) control, no nutraceutical 
(CON); or 500 mg/g of turmeric as 2) 95% turmeric (TUR); 3) 95% curcumin (CUR); or 4) 95% 
liposomal-curcumin (LIPC). All turmeric treatments significantly decreased (P = 0.006) SBEC 
compared to CON. Both CON and TUR had significantly lower (P = 0.0001) concentrations of 
C. difficile. These results, along with the numerical decreases in bacterial concentrations, when 
compared to CON were the criteria used to select LIPC for the second batch culture. The follow-
up in vitro 24 h batch culture examined four different dosages (15 g, 20 g, 25 g, and 30 g) of 500 
mg/g of LIPC, at reducing the concentration of opportunistic bacteria. These results were utilized 
to determine the dosing rate in the follow-up study, in vivo.  
INTRODUCTION 
Gut microbiota are one of the densest, most dynamic, and complex microorganism 
populations located in the body (Costa et al., 2012). Gut flora act against pathogens, aid in 
digestion and absorption, and stimulate the immune system (Suchodoiski et al., 2012). If the 
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microbiome is altered, this could result in gastrointestinal diseases such as enterocolitis, diarrhea, 
colic, and even death. C. perfringens, C. difficile, E. coli general and K-12, and S. bovis/equinus 
complex (SBEC) are common bacteria found in the microbiome. These five strains are 
considered to be opportunistic bacteria, and if the immune system becomes compromised or 
changes occur to the normal gut flora, this could trigger an increase of opportunistic bacteria that 
may result in numerous gastrointestinal diseases such as diarrhea and enterocolitis (Suchodoiski 
et al., 2012).  
To help aid in preventing gastrointestinal diseases associated with inflammation, such as 
enterocolitis, many horse owners supplement their horses with turmeric, at a suggested dosage of 
15 g, once daily (Kellon, 2012). Turmeric is a rhizomatous herbaceous perennial plant, Curcuma 
longa Linn, belonging to the ginger family, Zingiberaceae, and has been used for thousands of 
years in Ayurvedic medicine (Chan et al., 2009). Curcumin, the active ingredient in turmeric, has 
been suggested to have numerous medicinal benefits, including anti-inflammatory, antioxidant, 
antimicrobial, and wound healing properties, with a relatively low risk of adverse side effects 
(Zhu et al., 2014). However, due to its low bioavailability, curcumin can be encapsulated in 
liposomes in hopes to increase bioavailability. Although turmeric and curcumin, are considered 
relatively safe, little is known about their anti-microbial effects in the equine hindgut and at what 
dosage rate is it effective. The objective of this first batch culture in vitro study was to determine 
what form of 500 mg/g of turmeric, 95% turmeric, 95% curcumin, or 95% liposomal-curcumin, 
had the greatest effect on opportunistic bacteria in the equine hindgut microbiome. The follow-
up batch culture in vitro study was to determine what dosage of 500 mg/g of 95% liposomal-
curcumin had the greatest effect on reducing the opportunistic bacteria in the equine hindgut 
microbiome. 
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MATERIALS AND METHODS 
Animals 
 Four cecally-cannulated horses (Beard et al., 2011) weighing 522.95 ± 16.59 kg and 
having a BCS of 5.5 ± 0.5, were used for the two in vitro batch culture experiments and in the in 
vivo study. Southern Illinois University Animal Care and Use Committee (Protocol 14-048) 
approved care and handling of animals used in this study. Cannulated horses utilized in this study 
had not received any medical treatment one month prior to the start of this study and there were 
no concurrent medical issues between experiments nor during any of the studies.  
Batch Culture 
Treatments and Sample Collection 
Two, 24 h, in vitro batch cultures were conducted to determine the form and dose of 
turmeric to be utilized in vivo. The first in vitro batch culture examined which form of the 
nutraceutical, turmeric, at 500 mg/g, 95% turmeric, 95% curcumin, or 95% liposomal-curcumin 
(with the other 5% comprising of cellulose, magnesium stearate, vegetable source, and silicon 
dioxide) (Life Xtend Labs, Las Vegas, NV), had the greatest effect on reducing opportunistic 
bacteria, E. coli general and K-12, C. difficile, C. perfringens, and SBEC, found in the hindgut of 
equine. Erlenmeyer flasks (125 mL) were randomly assigned to one of the following treatments, 
in quadruplicate: 1) control, no nutraceutical (CON); or 500 mg/g of turmeric as 2) 95% turmeric 
(TUR); 3) 95% curcuma (CUR); or 4) 95% liposomal-curcumin (LIPC). Dosages (0.025 g, 0.033 
g, 0.042 g, and 0.05 g) were based off recommended dosage of 500 mg/g of turmeric at 15 g per 
454.54 kg horse (Farinacci et al., 2009; Casie, 2014). Erlenmeyer flasks also contained 0.50 g 
(Bailey et al., 2003) of ground alfalfa hay.  
  
81 
Cecal fluid was collected from four cecally-cannulated horses (2.5 L/horse) and 
composited to eliminate animal variation. Cecal samples were filtered through eight layers of 
cheesecloth to remove fibrous debris. Prior to incubation in the water bath, a 0 hour sample was 
collected, stored in a 15 mL conical tube, and frozen at -80° C for later analysis. Composited 
cecal fluid was mixed with McDougall’s buffer at a 1:4 ratio (Bailey et al., 2003). Then 50 mL 
of cecal fluid-buffer mix was poured into 16-125 mL Erlenmeyer flasks, degassed with CO2, and 
placed in a water bath at 39° C. Flasks were manually shaken every two hours for 24 h. At 24 h, 
the flasks were pulled from the water bath and total contents were aliquoted into 15 mL conical 
tubes and frozen at -80° C for subsequent laboratory analysis.  
The second in vitro 24 h batch culture examined the effect of dose on bacteria 
concentrations when supplementing LIPC. The LIPC treatment was selected based on results 
from the first in vitro batch culture. Erlenmeyer flasks (125 mL) were randomly assigned to one 
of the following treatments, in quadruplicate: 500 mg/g of LIPC at 1) recommended dose, (15); 
2) 1.33 times the recommended dose, (20); 3) 1.66 times the recommended dose (25); or 4) two 
times the recommended dose, (30). Dosages were based off recommended dosage of 500 mg/g of 
turmeric at 15 g per 454.54 kg horse (Farinacci et al., 2009; Casie, 2014) and were increased in 5 
g increments up to two times the recommended dose. The 125 mL Erlenmeyer flasks also 
contained 0.50 g (Bailey et al., 2003) of ground alfalfa hay. The in vitro protocol was the same as 
previously discussed except for pH measurements taken at 0 and 24 h with an Oakton pH 110 
Advanced Portable Meter (Vernon Hills, IL). 
Growth of Bacteria 
 Pure cultures of selected opportunistic bacteria were grown and used as standards for 
qPCR. Luria-Bertani medium was made for E. coli general and K-12, and Trypticase soy yeast 
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extract medium was made for SBEC, according to Deutsche Sammlung von Mikroorganismen 
und Zellkulturen GmbH (DSMZ) (Germany) media recipes. Clostridium medium was made for 
both C. difficile and C. perfringens, according to DifcoTM (Becton, Dickson and Company, 
Sparks, MD). Ten mL of broth was pipetted into glass Hungate tubes and deoxygenated with 
nitrogen. Rubber stoppers and metal caps were crimped on the tubes and then autoclaved at 121° 
C, 15 psi, for 15 min. Hungate tubes were inoculated with pelleted strains of E. coli, C. difficile, 
C. perfringens, and SBEC. Dense bacterial samples were transferred to a new Hungate tube 
every three days for 10 d to ensure pure cultures (Deutsche Sammlung von Mikroorganismen 
und Zellkulturen GmbH (DSMZ) (Germany)).  
DNA Extraction 
DNA was extracted from the cecal fluid samples using PowerSoil Mo Bio DNA 
Extraction Kits (Mo Bio Laboratories, Carlsbad, CA). The pure cultures that were used as 
standards for qPCR (Bio-Rad MyiQ Optical System Software 2.0) were extracted using 
PowerSoil Mo Bio DNA Extraction Kits (Mo Bio Laboratories, Carlsbad, CA) and then purified 
using UltraClean 15 DNA Purification Kits (Mo Bio Laboratories, Carlsbad, CA). All DNA 
extractions were assessed for concentration and quality using a Nano Drop ND-1000 
Spectrophotometer (Wilmington, DW). 
Real Time PCR  
All real-time PCR runs were performed in triplicate, and each reaction mixture was 
prepared using Maxima SYBR Green/ROX qPCR (Thermo Scientific, Waltham, MA). The total 
volume of the reaction mixture consisted of 216 ng of sample, 12.5 μL 1X SYBER Green master 
mix, and 2 uL of forward and reverse primers (Table 4.1). Standards were set to 10-fold dilution 
at 35, 3.5, 0.35, 0.035, 0.0035, 0.00035, 0.000035, and 0.0000035 ng, in duplicates. The thermal 
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cycling protocol for E. coli general and K-12 were as follows: initial denaturation for 10 min at 
95° C, followed by 40 cycles of 5 s at 95° C, 5 s at 60° C, and 5 s at 72° C. After amplification, 
the melting peak was cooled down over 15 s to 65° C (Lee et al., 2007). The thermal cycling 
protocol for C. difficile was as follows: initial denaturation for 10 min at 95° C, followed by 45 
cycles of 15 s at 95° C and one min at 60° C. After amplification, the reaction mixture was 
heated over 15 s to 65° C, for the melt curve (Avbersek et al., 2011). The thermal cycling 
protocol for C. perfringens was as follows: initial denaturation for 10 min at 95° C, followed by 
45 cycles of 15 s at 95° C, 20 s at 56° C, and 20 s at 72° C. After amplification, the reaction 
mixture was heated over 10 s to 65° C, for the melt curve (Karpowicz et al., 2009). The thermal 
cycling protocol for SBEC was as follows: initial denaturation for 10 min at 95° C, followed by 
40 cycles of 15 s at 95° C, 30 s, annealing at 60° C, and a 10 s melting curve at 65° C (Hastie et 
al., 2008). 
Statistical Analysis 
The in vitro experiments were analyzed as a completely randomized design using the 
MIXED procedure of SAS (SAS 9.4 Inst., Inc., Cary, NC). Flask was the experimental unit and 
the model included the effect of treatment. The significance level was set at (P ≤ 0.05).   
RESULTS AND DISCUSSION 
All nutraceutical treatments significantly decreased (P = 0.006) SBEC concentrations 
compared to CON, but CUR and LIPC significantly increased (P = 0.001) C. difficile compared 
to CON (Table 4.2). It is possible that the treatments did not decrease all the opportunistic 
bacteria for two reasons. First, this was only a 24 h in vitro batch culture using cecal fluid and 
may not have been long enough to see significant decreases (Bailey et al., 2003). Second, it may 
be possible that the dose used, was not enough (Farinacci et al., 2009; Casie, 2014). Curcumin, 
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the active ingredient of turmeric, is known and widely used for its medical benefits, including 
anti-inflammatory, antioxidant, antimicrobial, wound healing, and anti-tumor properties 
(Robson, 1959). However, curcumin has a low bioavailability due to its hydrophobic properties, 
low intrinsic activity, poor absorption, and high rate of metabolism and elimination from the 
body (Anard et al., 2009). To improve this, when encapsulated in liposomes, which are highly 
hydrophilic, curcumin may potentially have increased bioavailability, which increases its 
beneficial potency. Based on the literature and the results of this study, LIPC was utilized in the 
second in vitro batch culture to examine the effects of increasing doses on opportunistic bacteria 
concentrations. 
Follow-up In Vitro 
In the follow-up in vitro study, every flask had a pH within the normal equine cecum pH range 
of 6.5-7.1 (data not shown) and was not significantly different (P = 0.54) among treatments 
(Willard et al., 1977). The recommended dose (15) significantly decreased (P < 0.0001) SBEC 
concentrations compared to increasing doses of LIPC (Table 4.3). E. coli substrain K-12 
concentrations were decreased (P = 0.01) with 15 and 20 treatments compared to 25 and 30 
treatments. Concentrations of E. coli general were significantly less (P = 0.03) for 15, 20, and 30 
compared to the 25 treatment. Doses of LIPC had no effect (P ≥ 0.42) on C. difficile and C. 
perfringens, but numerically, 30 had the lowest concentration of C. difficile, and 25 had the 
lowest concentration of C. perfringens out of the four treatments. Previous work, with human 
subjects, showed E. coli substrain K-12 possesses curcumin-converting activity, which is 
responsible for curcumin transformation and slowing down the degradation and metabolic 
process of curcumin (Hassaninasab et al., 2011). Thus, increasing the dosage of LIPC may have 
increased the growth activity of E. coli general and K-12. In addition, due to curcumin being 
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broken down in the cecum of humans, this could have had a direct effect on these strains, and 
may be the reason for the observed responses (Hassaninasab et al., 2011). A follow-up study 
needs to be conducted examining the therapeutic effects of liposomal-curcumin and determine if 
oral dosing at different dosages elicits negative side effects. 
CONCLUSION 
In conclusion, based on the literature and previous work on turmeric and its active 
ingredient, curcumin, and their medical properties, this study supports the theory that 
encapsulating curcumin in liposomes is associated with increased bioavailability, potentially 
resulting in heightened medicinal benefits, specifically, antimicrobial properties compared to 
non-encapsulated forms. In the second in vitro batch culture, there was an unexplainable 
concentration response that may or may not have been related to curcumin-converting enzyme 
activity. Liposomal-curcumin demonstrated antimicrobial properties in reducing opportunistic 
bacteria, including C. perfringens, C. difficile, E. coli general and K-12, and SBEC, which are 
documented for causing foal-heat diarrhea, enterocolitis, and colic. Future in vivo studies are 
required to determine the causes of the concentration responses seen in these in vitro 24 h batch 
cultures. 
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Table 4.1. Forward and reverse primers used for qPCR in five opportunistic strains of bacteria found in equine cecal fluid  
   
1Streptococcus bovis/equinus complex (Hastie et al., 2008) 
2Escherichia coli general (Lee et al., 2007) 
3Escherichia coli substrain K12 (Lee et al., 2007) 
4Clostridium difficile (Magdesian and Leutenegger, 2010) 
5Clostridium perfringens (Karpowicz et al., 2009)
 
Strains 
   
Reverse Primers (5’-3’) 
   
MW 
(g/mol)  
 
Conc 
(nmol) 
Forward Primers (5’-3’) MW 
(g/mol) 
Conc 
(nmol) 
SBEC1 
E. coli K-122 
E. coli general3 
C. difficile4 
C. perfringens5 
GCCTACATGAAGTCGGAATCG            
TACAAGGCCGGGAACGTA 
GCTACAATGGCGCATACAAA              
TTCATGGAGTCGAGTTGCAG 
GTTAATACCTTTGCTCATTGA 
6455.3
6119.0 
6386.3 
7696.1 
5894.9 
59.2 
60.4 
52.6 
64.5 
58.3 
CAAGTTGAGCGATTTACTTCGGTAA  
CTAATCAGACGCGGGTCCAT      
AAATGTAACAGCAGGGGCA                 
TGAAATTGCAGCAACTCTAGC 
ACCAGGGTATCTAATCCTGTT 
6455.3 
6188.1 
6396.3 
6102.0 
6414.3 
61.3 
62.0 
54.5 
59.3 
32.4 
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Table 4.2. Effects of 500 mg/g of 95% turmeric, 95% curcumin, and 95% liposomal- 
 
curcumin, on opportunistic bacteria (ng/μL) found in equine cecal fluid 
 
 Treatment1   
               
P-value Strains CON TUR CUR LIPC SEM 
SBEC2 9.53E+04a 3.30E+04b  3.12E+04b  1.66E+04b  1.31E+04 0.006 
E. coli K-12 1.96E+01  1.08E+02  1.58E+01 3.80E+01 4.70E+01 0.51 
E. coli general 1.67E+01  2.20E+01 8.06E+01 2.62E+01 1.87E+01 0.11 
C. difficile 5.80E-01a   1.06ab  4.23c      2.07b  3.77E-01 0.0001 
C. perfringens 5.20E-01   1.26 2.10E-01  1.40E-01  4.09E-01 0.24 
  
a-cMeans ± SEM within a row with different superscripts differ (P < 0.05). 
1Treatments: CON = control (no nutraceutical); TUR = 0.025 g of 500 mg/g 95% turmeric; CUR 
= 0.025 g of 500 mg/g 95% curcumin; LIPC = 0.025 g of 500 mg/g 95% liposomal-curcumin.  
2Streptococcus bovis/equinus complex 
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Table 4.3. Effects of different dosages of 500 mg/g of 95% liposomal-curcumin on opportunistic 
bacteria (ng/μL) found in equine cecal fluid 
 Treatment1   
               
P-value Strains 15 20 25 30 SEM 
SBEC2 5.49E+09a            1.79E+11b       5.07E+13c     2.60E+12d    2.73E+07 <0.0001 
E. coli K-12 7.93E+03a          1.30E+04a     2.86E+06b  3.39E+06b      7.67E+05 0.01 
E. coli general 1.30E+02a             9.60E+01a     2.08E+04b    4.81E+03a       4.85E+01 0.03 
C. difficile 2.14E+03              1.74E+03      2.15E+01       1.07                        1.33E+03 0.56 
C. perfringens 5.20E-01   1.74E-02      2.06E-01      6.56E+01       3.20E+01 0.42 
 
a-dMeans ± SEM within a row with different superscripts differ (P < 0.05). 
1Treatments: 15 = 0.025 g of 500 mg/g 95% liposomal-curcumin; 20 = 0.033 g of 500 mg/g 95% 
liposomal-curcumin; 25 = 0.042 g of 500 mg/g 95% liposomal-curcumin; 30 = 0.05 g of 500 
mg/g 95% liposomal-curcumin.  
2Streptococcus bovis/equinus complex 
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CHAPTER 5 
EFFECTS OF LIPSOMAL-CURCUMIN ON BACTERIA FOUND IN THE EQUINE 
HINDGUT- AN IN VIVO STUDY 
ABSTRACT: 
The purpose of this study was to investigate the dose of turmeric and its active ingredient, 
curcumin, on reducing opportunistic bacteria found in the equine hindgut. The bacterial strains of 
interest included, Streptococcus bovis/equinus complex (SBEC), Escherichia coli K-12, 
Escherichia coli general, Clostridium difficile, and Clostridium perfringens. This study utilized 
four cecally-cannulated horses to determine the efficacy of antimicrobial and anti-inflammatory 
properties when oral dosing, increasing levels of liposomal-curcumin dosed at 15, 25, and 35 g 
compared to a control. In vivo, liposomal-curcumin’s antimicrobial properties, at 15 g, 
significantly decreased (P = 0.02) SBEC compared to other treatments. In addition, C. 
perfringens tended (P = 0.12) to decrease as liposomal-curcumin doses increased. Acetate tended 
to increase linearly (P = 0.10), as the dose of liposomal-curcumin increased. Valerate was 
greatest (P = 0.02) in control horses compared to liposomal-curcumin treated horses. Butyrate 
tended (P = 0.01) to increase in the control group and horses dosed liposomal-curcumin at 15 g. 
Treatment did not affect any of the other individual VFAs measured (P ≥ 0.54), but increasing 
doses of liposomal-curcumin tended (P = 0.10) to increase total VFA concentrations. Lastly, no 
adverse side effects were observed, suggesting these dosages are relatively safe. In regard to 
these findings, further projects need to be conducted to examine oral administration of 95% 
liposomal-curcumin with a longer acclimation period to study the potential therapeutic anti-
inflammatory properties and anti-microbial properties on the cecal microbiome of horses.  
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INTRODUCTION 
Horses may suffer from inflammation issues in their gastrointestinal (GI) tract, colic, 
enterocolitis, diarrhea, and inflammatory bowel disease, and joints, arthritis, osteochondritis, and 
bursitis. Additionally, due to the magnitude of stress applied to the joints, cartilage begins to 
break down, resulting in pain, inflammation, and osteoarthritis (Todhunter and Lust, 1990). 
Inflammation in horse’s GI tract can cause enterocolitis and colic due to physiological changes 
that can affect the balance of the microbiome in the cecum (Todhunter and Lust, 1990). If the 
microbiome is changed, this could result in gastrointestinal disease and even death. C. 
perfringens, C. difficile, E. coli general and K-12, and SBEC are common bacteria found in the 
microbiome of the hindgut. These strains are considered opportunistic bacteria, and 
inflammation, stress, and pain along with a compromised immune system changes the hindgut 
microbiome which can trigger proliferation of harmful and opportunistic bacteria that can cause 
numerous gastrointestinal diseases. Both C. perfringens and C. difficile can cause colitis and 
diarrhea in horses, E. coli can lead to enterocolitis, and SBEC can affect the lactic acid bacteria 
concentration in the hindgut and can trigger inflammatory cytokines (Mackie and Wilkins, 1988; 
Todhunter and Lust, 1990). 
 Commonly, osteoarthritis and GI diseases caused from dysbiosis or inflammation can be 
managed with non-steroidal anti-inflammatory drugs (NSAIDs) to reduce pain (Ricciotti and 
FitzGerald, 2011). NSAIDs are used to alleviate pain and inflammation by suppressing 
eicosanoids and inhibiting cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). Since 
NSAIDs inhibit COX-1, common side effects are GI bleeding, ulcers, colitis, and colic 
(Farinacci et al., 2009). Due to the many adverse side effects, there is a high demand for 
alternative treatments, such as nutraceuticals.  
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Curcumin is the active ingredient in turmeric, Curcuma longa. Over the past 30 years, 
studies in horses, humans, and mice, have shown that curcumin has properties that can manage 
and prevent a magnitude of inflammatory diseases while being nontoxic to metabolic pathways 
(Prasad et al., 2014). Curcumin also possesses antimicrobial properties, which have been studied 
in humans, chickens, and horses (Mackie and Wilkins, 1988; Prasad et al., 2014; El-Bahy and 
Bazh, 2015). The antimicrobial properties could aid in preventing pathogenic and opportunistic 
bacteria found in the hindgut from proliferating and causing GI issues. However, while curcumin 
seems to be the ideal alternative treatment for a wide variety of diseases, it has poor 
bioavailability (Prasad et al., 2014). Curcumin’s poor bioavailability, observed in humans, dogs, 
and mice, is related to its hydrophobic properties and quick elimination from the body (Prasad et 
al., 2014). However, past studies have speculated that encapsulating curcumin in liposomes 
could increase its bioavailability (Prasad et al., 2014). The primary objective of this research was 
to evaluate the antimicrobial properties of liposomal-curcumin (LIPC) in an in vivo study. The 
secondary objective was to determine if increasing doses would elicit a negative effect on cecal 
characteristics and blood parameters. And lastly to examine range of motion and therapeutic 
effects of orally administered liposomal-curcumin in cecally-cannulated horses.  
MATERIALS AND METHODS 
Animals 
 Four Southern Illinois University-owned, cecally-cannulated horses (Beard et al., 2011), 
weighing 522.95 ± 16.59 kg and having a BCS of 5.5 ± 0.5, were used for the two in vitro batch 
culture experiments and in the in vivo test. Southern Illinois University Animal Care and Use 
Committee (Protocol 14-048) approved care and handling of animals used in this study. None of 
the horses utilized in this study were given any medication one month prior to the start of this 
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study or between experiments and they had no concurrent medical issues at the initiation of, nor 
during the study.  
Treatment and Sample Collection 
 Four cecally-cannulated horses were utilized in a 4 x 4 Latin square to evaluate 
increasing doses of LIPC on the same opportunistic bacteria stated in Chapter 4, and to evaluate 
cecal characteristics as well as inflammation. Horses were randomly assigned to one of four 
treatments: 1) no LIPC, (0); 2) 15 g of 500 mg/g of LIPC, recommended dose (15); 3) 25 g of 
500 mg/g of LIPC (25); or 4) 35 g of 500 mg/g of LIPC (35). Horses were fed 2-3 lbs of 
Strategy® (Purina Mills, St. Louis, MO), once a day at 0600 and the treatments were top-dressed 
on the grain. Strategy was used for treatment delivery and to maintain a BCS of 5-6. Once grain 
and treatment was consumed horses were then turned out to pasture (predominantly K31 Tall 
Fescue) and allowed to graze until 1600, at which time they were stalled and fed hay that was cut 
from the same pasture the previous hay season. This was the daily procedure with the exception 
of d 9 for each period, during which they were stalled all day and had ab libitum access to hay 
and water after complete consumption of Strategy® and treatment.  
Each period was 14 days with a 9 d acclimation period and a 5 d withdrawal period 
(Weese et al., 2003; Farinacci et al., 2009). Cecal fluid was collected at 0 h on d 0 and 8, and 
again on d 9 at 0, 3, 6, 9, 12, 15, 18, and 21 h. Whole cecal contents (100 mL) were collected, pH 
recorded (Oakton pH 110 Advanced Portable Meter (Vernon Hills, IL), subsampled (15 mL), 
and immediately frozen for later analysis of opportunistic bacteria. On d 9, after pH was 
recorded, contents were filtered through eight layers of cheesecloth into a 15 mL collection tube 
and immediately frozen for later analysis of VFA and ammonia concentrations. Blood was also 
collected via jugular venipuncture on d 0 and 8 into a serum separator tube and a 7.5% 
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Ethylenediaminetetraacetic acid (EDTA) tube (Coviden, Mansfield, MA) for chemistry panel 
analysis, complete blood count analysis, and erythrocyte sedimentation rate assessment. On d 0 
and 8, range of motion was measured for the knee and hock joints, using a universal goniometer 
(Valley Vet, Marysville, KS) (McGann et al., 2013).  
Growth of Bacteria 
 Pure cultures of selected opportunistic bacteria were grown and used as standards for 
qPCR. Luria-Bertani medium (10 g/L tryptone, 5 g/L yeast extract, and 10 g/L NaCl) was made 
for E. coli general and K-12, and Trypticase soy broth (30 g/L) and yeast extract (3 g/L) medium 
was made for SBEC, according to Deutsche Sammlung von Mikroorganismen und Zellkulturen 
GmbH (DSMZ) (Germany) media recipes. Clostridium medium (17 g/L digest casein, 3 g/L 
digest soy, 5 g/L NaCl, 2.5 g/L K2Pho4 and dextrose) was made for both C. difficile and C. 
perfringens, according to DifcoTM (Becton, Dickson and Company, Sparks, MD). Ten mL of 
broth was pipetted into glass Hungate tubes and deoxygenated with nitrogen. Rubber stoppers 
and metal caps were crimped on the tubes and then were autoclaved at 121° C, 15 psi, for 15 
min. Hungate tubes were inoculated with pelleted strains of bacteria, E. coli, C. difficile, C. 
perfringens, and SBEC. Dense bacterial samples were transferred to a new Hungate tube every 3 
d for 10 d to ensure pure cultures (Deutsche Sammlung von Mikroorganismen und Zellkulturen 
GmbH (DSMZ) (Germany)).  
DNA Extraction 
DNA was extracted from the cecal fluid samples using PowerSoil Mo Bio DNA 
Extraction Kits (Mo Bio Laboratories, Carlsbad, CA). The pure cultures that were used as 
standards for qPCR (Bio-Rad MyiQ Optical System Software 2.0) were extracted using 
PowerSoil Mo Bio DNA Extraction Kits (Mo Bio Laboratories, Carlsbad, CA) and then purified 
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using UltraClean 15 DNA Purification Kits (Mo Bio Laboratories, Carlsbad, CA). All DNA 
extractions were assessed for concentration and quality using a Nano Drop ND-1000 
Spectrophotometer (Wilmington, DW). 
Real Time PCR  
All real-time PCR runs were performed in triplicate, and each reaction mixture was 
prepared using Maxima SYBR Green/ROX qPCR (Thermo Scientific, Waltham, MA). The total 
volume of the reaction mixture consisted of 216 ng of sample, 12.5 μL 1X SYBER Green master 
mix, and 2 uL of forward and reverse primers (Table 4.1). Standards were set to 10-fold dilution 
at 35, 3.5, 0.35, 0.035, 0.0035, 0.00035, 0.000035, and 0.0000035 ng, in duplicates. The thermal 
cycling protocol for E. coli general and K-12 were as follows: initial denaturation for 10 min at 
95° C, followed by 40 cycles of 5 s at 95° C, 5 s at 60° C, and 5 s at 72° C. After amplification, 
the melting peak was cooled down over 15 s to 65° C (Lee et al., 2007). The thermal cycling 
protocol for C. difficile was as follows: initial denaturation for 10 min at 95° C, followed by 45 
cycles of 15 s at 95° C and one min at 60° C. After amplification, the reaction mixture was 
heated over 15 s to 65° C, for the melt curve (Avbersek et al., 2011). The thermal cycling 
protocol for C. perfringens was as follows: initial denaturation for 10 min at 95° C, followed by 
45 cycles of 15 s at 95° C, 20 s at 56° C, and 20 s at 72° C. After amplification, the reaction 
mixture was heated over 10 s to 65° C s for the melt curve (Karpowicz et al., 2009). The thermal 
cycling protocol for SBEC was as follows: initial denaturation for 10 min at 95° C, followed by 
40 cycles of 15 s at 95° C, 30 s, annealing at 60° C, and a 10 s melting curve at 65° C (Hastie et 
al., 2008). 
Serum Chemistry Panel and Complete Blood Count Assays 
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 Blood samples were separated via centrifugation to collect serum and transferred to a red 
top tube for evaluation (Coviden, Mansfield, MA). Serum was analyzed for liver (total protein, 
ALT, and ALP), kidney (BUN and creatinine), and blood glucose level with an Abaxis VetScan 
V2 (Union City, CA). Blood collected into tubes containing 7.5% EDTA, was analyzed for 
complete blood count, including a five-part differential (neutrophils, lymphocytes, monocytes, 
eosinophils, and basophils) with an Abaxis VetScan HM5 (Union City, CA). Whole blood was 
also analyzed for inflammation by performing an erythrocyte sedimentation rate test using the 
Autozero Westergren Erythrocyte Sedimentation Rate (ESR) system (Globe Scientific Inc., 
Paramus, NJ). 
Ammonia and Volatile Fatty Acid Analysis 
 Cecal NH3 concentrations were determined by the phenol-hypochlorite procedure 
(Broderick and Kang, 1980). Cecal fluid was analyzed for VFA concentrations (Goetsch and 
Galyean, 1983) using a Shimadzu GC-2010 gas chromatograph (Shimadzu Scientific 
Instruments, Inc., Columbia, MD) equipped with a flame-ionization detector and 30-m SP-2560 
fused silica capillary column (Restek Stabil WAX DA column, Bellefonte, PA). The internal 
standard 2-ethyl butyrate was used for VFA analysis (Goetsch and Galyean, 1983). The helium 
carrier gas was maintained at a linear velocity of 23 cm/s. The oven temperature was 
programmed to 65º C for 3 min, increased at 12º C/min to a final temperature of 225º C, which 
was held for 9 min. The column temperature was maintained at 65º C and the flame ionization 
detector temperature at 225º C. 
Statistical Analysis 
Bacterial concentrations, ESR, chemistry panel data, complete blood count data, and 
goniometer range of motion data was analyzed using the MIXED procedure of SAS (SAS 9.4 
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Inst., Inc., Cary, NC) using the model for a Latin square design with a Tukey post-hoc 
adjustment. The model included treatment and period with animal specified in the RANDOM 
statement of SAS. Cecal fermentation data (NH3, pH, and VFA) were analyzed using the 
MIXED procedure of SAS for repeated measures. The model included period, treatment, and 
time as well as treatment × time interactions. The RANDOM statement of SAS included the 
interaction of period × time within subject. An autoregressive covariance structure (AR1 of the 
MIXED procedure of SAS) was determined to be most appropriate based on Akaike’s 
Information Criterion. There were no treatment x time interactions; therefore, only treatment 
means are reported. Comparisons of main effects were determined using least square means and 
Fisher’s protected LSD. Calculation of coefficients for linear orthogonal polynomials with 
unequal spacing was done using IML of SAS (Robson, 1959). Significance was set at (P = 0.05) 
and tendency was set at (P ≤ 0.15).    
RESULTS AND DISCUSSION 
Based on the results of the batch cultures, in the previous chapter, the authors decided to 
investigate 15 g, 25 g, and 35 g of 500 mg/g of 95% LIPC for the in vivo study. Day 0 samples 
confirmed that opportunistic bacteria were present. SBEC bacterial concentrations increased 
linearly (P = 0.008) as LIPC dose increased, but concentrations were similar for 0 and 15 (Table 
5.1). As the dose of LIPC increased the concentration of C. perfringens decreased linearly (P = 
0.03). The remaining three opportunistic bacteria strains, C. difficile, E. coli general, and E. coli 
K-12, were not significant (P ≥ 0.20) across treatments. Numerically, 25 had the lowest 
concentration of E. coli general, and 0 had the lowest concentration of C. difficile. Although 
increasing the dose of LIPC decreased C. perfringens the observation that increasing the dose 
also increases SBEC would suggest that there may be no additional benefit of dosing LIPC 
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above the recommended rate. However, this would also suggest that the nutraceutical reaches the 
cecum without being compromised in the stomach during the digestion process.  
Parameters of inflammation, including ESR (P = 0.87) and range of motion (P ≥ 0.24) 
were not significant among treatments (Table 5.2). Additionally, all blood work was within 
normal ranges (data not shown), suggesting that increasing the dose of LIPC has no negative 
effect. Interestingly, a numerical basis suggested that, 35 had the least amount of inflammation 
detected on the ESR test on d 8. The acclimation period of eight days may not have been long 
enough to show a significant improvement in inflammation blood parameters and range of 
motion. Therefore, further research needs to be conducted using LIPC over an extended period of 
time, such as 30 days, when looking at potential for decreasing inflammation parameters. A 
longer acclimation period may give the body enough time to respond to the anti-inflammatory 
properties and may yield a noticeable change in lameness, stiffness/soreness, and inflammation 
(Farinacci et al., 2009). 
There was no treatment x time interactions so only treatment means are reported. Cecal 
fluid pH was not significant among treatments (P = 0.82) (Table 5.3). All cecal pH 
measurements were within the normal range for the horse cecum, 6.5 - 7.1 (Anard et al., 2009). 
Cecal fluid ammonia concentrations were not significant among treatments (P = 0.21); however, 
concentrations tended (P = 0.11) to decrease linearly as LIPC dose increased. Valerate was 
significantly different among treatments (P = 0.02) with 0 having the greatest concentration 
compared to all other treatments. Moreover, valerate decreased linearly (P = 0.005) as LIPC dose 
increased. As LIPC dose increased, butyrate and iso-valerate decreased linearly (P ≤ 0.03). 
However, acetate tended to increase linearly (P = 0.10), as the dose of LIPC increased. 
Treatment did not affect any of the other individual VFAs measured (P ≥ 0.19), but increasing 
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doses of LIPC tended (P = 0.10) to increase total VFA concentrations. Additionally, LIPC 
tended (P = 0.11) to increase total VFA concentrations when compared to 0. This data not only 
suggests that administering LIPC at the recommended rate, 15 g, 25 g, or 35 g, for eight days, 
does not cause adverse side effects on digestion, inflammation, and blood parameters, but that 
when dosed for a longer period of time may increase digestibility (Bergman, 1990). Therefore it 
is being suggested that this nutraceutical is relatively safe, even at higher dosages (El-Bahy and 
Bazh, 2015).   
CONCLUSION 
In conclusion, based on the literature and previous work on turmeric and its active 
ingredient, curcumin, and their medicinal properties, this study supports the theory that 
encapsulating curcumin in liposomes can increase its bioavailability, potentially resulting in 
heightened medicinal benefits, specifically, antimicrobial properties, compared with non-
encapsulated forms. In the current investigation, the lack of significant concentration differences 
across selected opportunistic bacteria may be due to the potential need for a longer duration of 
the acclimation period. Further research needs to be conducted looking at similar dosages over 
an extended period of time to evaluate the anti-microbial and anti-inflammatory properties of 
500 mg/g of liposomal-curcumin. Overall, oral administration of curcumin at different dosages 
did not have any adverse side effects on digestion, blood parameters, or range of motion; 
therefore, it could potentially be used as an alternative treatment for GI conditions and 
inflammation  
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Table 5.1. Effects of 500 mg/g of 95% liposomal-curcumin at 0 g, 15 g, 25 g, and 35 g, on  
  
  Treatment1  
               P-value 
Strains 0 15 25 35 SEM TRT2 LIN3 
SBEC4 13.00ab 12.73a 13.68bc 14.12c 0.25 0.02 0.008 
E. coli K-12 20.46 19.16 19.73 20.50 1.49 0.20 0.96 
E. coli general 32.64 32.77 32.21 33.27 0.37 0.94 0.79 
C. difficile 29.61 29.68 30.63 31.15 1.01 0.62 0.25 
C. perfringens 49.18 46.36 45.97 43.51 1.36 0.12 0.03 
 
a-c Treatment means ± SEM within a row with different superscripts differ (P < 0.05). 
1Treatments: 0 = control (no nutraceutical); 15 = 15 g of 500 mg/g 95% liposomal-curcumin; 25 
= 25 g of 500 mg/g 95% liposomal-curcumin; 35 = 35 g of 500 mg/g 95% liposomal-curcumin.  
2P-value for treatment means. 
3P-value for linear contrast. 
4 Streptococcus bovis/equinus complex
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Table 5.2. Effects of 500 mg/g of 95% liposomal-curcumin at 15 g, 25 g, and 35 g, on 
inflammation in the blood and degree of range of motion  
  Treatment1  
      
SEM 
         P-value 
Item 0 15 25 35 TRT2 LIN3 
ESR4 86.36 89.88 87.85 80.89 7.22 0.87 0.67 
Right Knee 100.00 97.89 93.75 98.75 3.44 0.44 0.56 
Right Hock 86.25 90.00 87.50 81.25 3.46 0.51 0.36 
Left Knee 95.35 92.96 92.77 92.66 3.12 0.88 0.54 
Left Hock 87.51 91.12 84.90 84.90 3.95 0.36 0.24 
1Treatments: 0 = control (no nutraceutical); 15 = 15 g of 500 mg/g 95% liposomal-curcumin; 25 
= 25 g of 500 mg/g 95% liposomal-curcumin; 35 = 35 g of 500 mg/g 95% liposomal-curcumin.  
2P-value for treatment means. 
3 P-value for linear contrast. 
4Erythrocyte sedimentation rate test, mm/hr. 
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Table 5.3. Effects of 500 mg/g of 95% liposomal-curcumin at 0 g, 15 g, 25 g, and 35 g, on cecal 
fluid characteristics 
 Treatment1   
 
Item 
 
0 
 
15 
 
25 
 
35 
 P-value 
SEM TRT2 LIN3 
pH 6.71 6.68 6.68 6.67 0.03 0.82 0.38 
Ammonia, mg/dL 15.89 15.6 9.94 12.25 2.12 0.21 0.11 
Total VFA, mM 51.59 71.15 73.68 65.32 6.14 0.11 0.10 
        
VFA, mol/100mol        
   Acetate 35.53 36.64 36.64 40.91 1.98 0.28 0.10 
   Propionate 49.68 52.75 54.75 50.15 1.96 0.34 0.62 
   Isobutyrate 3.97 1.67 1.31 0.59 1.90 0.54 0.19 
   Butyrate 10.63 9.57 8.09 8.46 0.62 0.06 0.01 
   Isovalerate 0.40 0.13 0.14 0.08 0.09 0.10 0.03 
   Valerate 0.68a 0.32b 0.28b 0.24b 0.09 0.02 0.005 
 
a-c Treatment means ± SEM within a row with different superscripts differ (P < 0.05). 
1Treatments: 0 = control (no nutraceutical); 15 = 15 g of 500 mg/g 95% liposomal-curcumin; 25 
= 25 g of 500 mg/g 95% liposomal-curcumin; 35 = 35 g of 500 mg/g 95% liposomal-curcumin.  
2P-value for treatment means. 
3 P-value for linear contrast. 
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CHAPTER 6 
CONCLUSION 
 Turmeric is a rhizomatous herbaceous perennial plant, Curcuma longa Linn, belonging to 
the ginger family, Zingiberaceae (Chan et al., 2009). Curcumin, the active ingredient in turmeric, 
is gaining popularity for its anti-oxidant, anti-microbial, and anti-inflammatory properties. 
Curcumin has been used as medicine in Eastern countries for over a thousand years. In the past 
30 years, studies have shown that curcumin has properties that can treat and prevent a magnitude 
of inflammatory disease while being nontoxic to metabolic pathways (Prasad et al., 2014). 
Curcumin inhibits inflammation by down regulating pro-inflammatory adipokines, tumor 
necrosis factor (TNF), and interleukin (IL)-6 (Prasad et al., 2014). Curcumin also possesses 
antimicrobial properties, which can aid in decreasing harmful and opportunistic bacteria found in 
the equine hindgut, including SBEC, E. coli general and K-12, C. perfringens and C. difficile. 
However, while curcumin seems to be the ideal alternative treatment for a wide variety of 
diseases, it has poor bioavailability. Curcumin’s poor bioavailability is related to its hydrophobic 
properties and quick elimination in the body. Therefore, to increase curcumin’s bioavailability, 
studies have tried to encapsulate curcumin in liposomes to increase its hydrophilic properties (Li 
et al., 2007 and Li et al., 2011).  
 In a series of studies, investigating curcumin’s antimicrobial and anti-inflammatory 
properties in both, canines and equines. In the first study, the investigators observed that 95% 
curcumin at 500 mg, SID, can significantly reduce overall pain on day 60 and pain after physical 
exertion on day 90 in moderately arthritic canines. 95% curcumin (500 mg, SID) and 95% 
liposomal-curcumin (250 mg, BID) can decrease pain during manipulation at day 150 in 
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moderately arthritic canines. In the second project, a follow-up study to project one, 95% 
curcumin at 500 mg, SID, significantly decreased overall pain in moderately arthritic canines by 
day 60. 95% curcumin at 100 mg, SID, significantly decreased pain during limb manipulation by 
day 60. Both 95% curcumin at 100 mg and 500 mg, SID significantly decreased pain after 
physical exertion by day 60. By studying the anti-inflammatory properties of curcumin in 
moderately arthritic dogs, we concluded that both could significantly reduce overall pain, pain 
upon limb manipulation, and pain after physical exertion by day 60 out of a 150-day study. 
During both studies all 20 dogs had blood and chemistry parameters within normal range, the 
dogs did not experience any adverse side effects, concluding that giving curcumin as a 
nutraceutical to alleviate arthritic symptoms is safe. 
 In a two-part study, investigating the antimicrobial and anti-inflammatory properties of 
turmeric and curcumin on the bacteria found in the equine hindgut. Two in vitro, closed system, 
24 h batch culture studies were conducted, first to look at which form of turmeric, 95% turmeric, 
95% curcumin, and 95% liposomal-curcumin had the greatest effect on decreasing the 
opportunistic bacteria found in the equine hindgut, including SBEC, E. coli general and K-12, C. 
perfringens and C. difficile. Based on the results found in the first in vitro, a follow-up study was 
conducted looking at different dosages, 15 g, 20 g, 25 g, and 30 g, of 500 mg/g of 95% 
liposomal-curcumin had the greatest effect on decreasing the opportunistic bacteria found in the 
equine hindgut, including SBEC, E. coli general and K-12, C. perfringens and C. difficile. From 
these in vitro studies, it was concluded that the flasks that had the highest concentrations, SBEC, 
C. difficile, and C. perfringens, were the flasks with higher dosages of 95% liposomal-curcumin. 
Based on the results of the batch cultures, the authors decided to investigate 15 g, 25 g, and 35 g 
of 500 mg/g of 95% liposomal-curcumin for the in vivo study. This data not only suggests that 
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administering liposomal-curcumin at the recommended rate, 15 g, 25 g, or 35 g, for eight days, 
does not cause adverse side effects on digestion, inflammation, and blood parameters, but that 
when dosed for a longer period of time may increase digestibility (Bergman, 1990). Therefore, it 
is being suggested that curcumin is relatively safe, even at higher dosages, and could potentially 
be used as an alternative treatment for GI conditions and inflammation. In addition, the lack of 
significant concentrations differences in all selected opportunistic bacteria may be due to the 
potential need for a longer duration of the acclimation period. Further research needs to be 
conducted looking at similar dosages over an extended period of time to evaluate the anti-
microbial and anti-inflammatory properties of 500 mg/g of liposomal-curcumin, similar to the 
previous studies conducted on moderately arthritic canines.  
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